References

Guidelines and national guidance

These are syntheses rather than evidence in themselves, and they disagree with one another in ways that matter. Where the guidelines stand sets out how and why.

1. NICE NG238 — Cardiovascular disease: risk assessment and reduction, including lipid modification

   National Institute for Health and Care Excellence · Published 14 December 2023; last reviewed 2 September 2025

   SupportsUK lipid targets, the QRISK3 treatment threshold of 10%, and the statin intensities quoted throughout the heart topic.

   Read it asThe 2025 review added technology-appraisal links without changing recommendations. This is the document UK practice actually follows; the US and European numbers on this site do not override it.

   Strong

2. Summary of national guidance for lipid management

   NHS England / Accelerated Access Collaborative · Operational summary, updated periodically

   SupportsThe pathway most UK trusts work from in practice.

   Read it asHistorically carried the Joint British Societies targets of 1.8 and 2.5 mmol/L. A local protocol quoting those figures may predate alignment with NG238.

   Strong

3. 2026 ACC/AHA multisociety Guideline on the Management of Dyslipidemia

   Circulation; co-published in JACC 2026;87(19):2624–2757 · Online 13 March 2026

   SupportsPREVENT-ASCVD replacing the Pooled Cohort Equations, restored LDL-C and non-HDL-C goals, universal once-in-a-lifetime Lp(a) measurement, and the CAC-tiered targets.

   Read it asUS risk engines are calibrated on US populations. The targets are not transferable to UK practice, and NICE carries a cost-effectiveness constraint this document does not.

   Strong

4. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

   European Heart Journal 2025;46(42):4359–4378 · 7 November 2025; correction published February 2026

   SupportsThe European column of the target comparison table, and the Lp(a) risk threshold used in Europe.

   Strong

5. QRISK3

   ClinRisk / University of Nottingham · In current UK use

   SupportsThe 10-year risk figure the calculator asks for and the escalation thresholds built on it.

   Read it asValidated for ages 25–84 and calibrated on a UK primary-care population. It is the reason this site does not ship a second, cruder risk estimate alongside it. Note for clinicians: in October 2025 NICE removed the reference to the online QRISK3 from NG238, on the grounds that it should not be used for direct patient care — the version embedded in the clinical system is the one to use.

   Strong

Lipids, particles and causality

The claim doing the most work on this site is that lowering atherogenic particle count reduces events, and that it is causal rather than correlational. This is what that rests on.

1. Prevalence of LDL-C / apoB discordance

   Analyses of the Very Large Database of Lipids and of NHANES · 2015–2025

   SupportsThe “roughly one patient in five” figure in the clinical primer — discordance reported in about 20% of US adults, with a large real-world analysis finding around 21%.

   Read it asThe proportion moves substantially with how discordance is defined. In one recent cohort a median-based classification called 47.2% discordant, the clinically concerning high-apoB / low-LDL-C phenotype was 23.8%, and a ratio threshold gave 28.5%. One in five is the modal estimate and the useful one for a clinician; it is not a fixed property of the population, and the primer says so.

   Moderate

2. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies

   European Atherosclerosis Society Consensus Panel — Ference BA et al., European Heart Journal 2017;38(32):2459–2472 · 2017

   SupportsThat LDL/apoB is causal, and the Mendelian randomisation argument summarised on the misconceptions chapter.

   Read it asThe single most useful citation for a sceptical reader, because it is explicitly about whether the causal criteria are met rather than about a single trial.

   Strong

Measurement, variation and the LDL-C equations

The evidence behind chapter 2. Most misinterpretation of a lipid panel happens here rather than in the biology.

1. Biological variation of direct and calculated LDL-C

   Scandinavian Journal of Clinical and Laboratory Investigation, and a meta-analysis of 30 studies by Smith et al. covering 1970–92 · 2025 and earlier

   SupportsWithin-person variation of roughly 8.7% for direct LDL-C, 9.3% by Friedewald and 9.0% by Martin–Hopkins; about 6% for total cholesterol, 7% for HDL-C and 22–28% for triglycerides.

   Read it asThese are healthy-subject estimates under standardised protocols. Individual people vary in how variable they are — published series find some subjects under 4% and others over 12% for the same analyte. The reference change values quoted on this site are derived from these figures and are approximate by design.

   Strong

2. Variability of measured and calculated LDL-C in statin-treated patients

   Kilpatrick ES, Kallner A, Atkin SL, Sathyapalan T, Annals of Clinical Biochemistry · 2025

   SupportsThat the equations differ in how much variation they add on top of the biology: Friedewald 12.9%, Sampson–NIH 10.4%, Martin–Hopkins 9.3% against direct measurement, in patients on atorvastatin.

   Read it asSmall crossover study, 26 patients with type 2 diabetes. Directionally useful, not a precise population estimate.

   Moderate

3. Comparison of methods to estimate LDL-C in patients with high triglyceride levels

   JAMA Cardiology, from the Very Large Database of Lipids (111,939 patients) · 2021

   SupportsThat at triglycerides of 400–799 mg/dL (4.5–9.0 mmol/L) the extended Martin–Hopkins equation was classified as accurate against ultracentrifugation in 62.1% of cases by the study’s own criterion, versus 40.4% for Sampson and 19.3% for Friedewald. What counts as “accurate” is a predefined band in that paper, not a self-evident quantity, and the figure should not be quoted without it.

   Read it asThe authors advise caution with any estimation in this triglyceride range regardless of method. The site reflects that: above about 4.5 mmol/L, treat a calculated LDL-C as unusable rather than as approximately right.

   Strong

4. Discordance between the Friedewald, Sampson and Martin–Hopkins equations at clinical cut-points

   Analyses of US electronic health record cohorts, including 146,106 patients with established ASCVD · 2020–2024

   SupportsThat Friedewald and Martin–Hopkins disagree about whether a patient is below LDL-C 1.8 mmol/L in about 15% of cases at triglycerides under 4.5 mmol/L, with much higher discordance in the 2.0–4.5 mmol/L triglyceride band. Martin–Hopkins consistently returns the higher value.

   Read it asUS cohorts and mg/dL cut-points. The direction of the bias transfers to UK practice; the exact percentages should not be quoted as UK figures.

   Strong

5. Impact of fasting duration on LDL-C estimated by the Friedewald, Martin-Hopkins and Sampson/NIH equations

   Biochemia Medica 2025;35(2) · 2025

   SupportsThat non-fasting sampling lowers calculated LDL-C by roughly 0.26–0.32 mmol/L depending on the equation, which is the basis for the site advising consistency of fasting state when comparing two results.

   Moderate

Cardiovascular risk in women

1. 2024 AHA/ASA Guideline for the Primary Prevention of Stroke, and the 2026 multisociety dyslipidaemia guideline

   American Heart Association / American Stroke Association; and the 2026 ACC/AHA multisociety guideline · 2024 and March 2026

   SupportsThat pregnancy complications, premature and early menopause and endometriosis are now formally named as risk factors, and that early menopause, preeclampsia and gestational diabetes are named among the risk-enhancing factors that should refine cardiovascular risk assessment.

   Read it asThese are US guidelines. The recognition of obstetric history as cardiovascular data is not controversial, but no widely used UK risk calculator currently ingests it — which is the practical gap the chapter is about.

   Strong

2. Hypertensive disorders of pregnancy and later cardiovascular disease

   Systematic reviews and meta-analyses, including sex-specific stroke risk factor reviews summarising the 2024 guideline · 2022–2026

   SupportsRoughly two- to four-fold higher later hypertension and cardiovascular disease after preeclampsia, and around 81% higher stroke risk in meta-analysis; with early-onset and severe disease carrying more risk.

   Read it asObservational throughout, and it remains unsettled whether preeclampsia causes later disease or reveals a pre-existing susceptibility — the “failed stress test” reading. That distinction matters for research and not for what a patient should do.

   Strong

Omega-3 and the comparator controversy

Two large trials, opposite results, and a design difference nobody can rule out. Listed in full because the calculator page previously cited only the positive one.

1. REDUCE-IT — icosapent ethyl 4 g/day against mineral oil

   Bhatt DL et al., New England Journal of Medicine 2019;380:11–22 · 2019

   Supportsn=8,179, median 4.9 years. Primary composite 17.2% against 22.0%, HR 0.75 (0.68–0.83).

   Read it asThe mineral oil comparator did not behave inertly: LDL-C rose about 10%, apoB about 8% and hs-CRP about 32% in the placebo arm, with later analyses reporting rises in IL-6, Lp(a) and oxidised LDL. The placebo question was reviewed by the FDA, Health Canada and the EMA, all of which approved the drug; the trial investigators (Steg and Bhatt, Eur Heart J 2021) report that all three concluded any effect of placebo choice on the 25% risk reduction would have been very small — a characterisation that comes from the investigators rather than from a regulatory document quoted directly, which is worth knowing when weighing it. Critics including STRENGTH’s executive committee chair regard the result as a false positive. The strongest argument on the other side is JELIS, an open-label trial of EPA with no mineral oil, which reported a 19% reduction in coronary events.

   Contested

2. NICE TA805 — Icosapent ethyl with statin therapy

   National Institute for Health and Care Excellence · Published 13 July 2022

   SupportsWhat the UK actually funds: icosapent ethyl for secondary prevention only — established cardiovascular disease, on a statin, fasting triglycerides 1.7 mmol/L or above, LDL-C above 1.04 and at or below 2.60 mmol/L. Not recommended for primary prevention, where NICE judged it unlikely to be cost effective, and not applicable in familial hypercholesterolaemia.

   Read it asNICE recommended it on the REDUCE-IT evidence while the comparator debate was already public, and set eligibility to mirror the trial population. Worth knowing that NHS England otherwise advises against omega-3 for cardiovascular prevention with this as the single stated exception — so the everyday question is usually eligibility rather than efficacy.

   Strong

3. STRENGTH — omega-3 carboxylic acid (EPA+DHA) against corn oil

   Nicholls SJ, Lincoff AM, et al., JAMA 2020;324:2268–2280 · 2020

   Supportsn>13,000, stopped for futility in January 2020. The corn oil comparator did not raise LDL-C or inflammatory markers.

   Read it asBoth trials found increased atrial fibrillation on omega-3. The two explanations for the discrepancy — EPA alone differing from EPA+DHA, or the REDUCE-IT comparator inflating the effect — cannot be separated by either design. The trial that would settle it, icosapent ethyl against corn oil, has not been run.

   Strong

Inflammation and residual risk

Listed together and in order, because the direction of travel is the point. hs-CRP predicts risk well; whether lowering inflammation reduces events is a separate question and the recent large trials have gone the other way.

1. CANTOS — canakinumab, IL-1β inhibition

   Ridker PM et al., New England Journal of Medicine · 2017

   SupportsThat reducing a specific inflammatory pathway can reduce cardiovascular events with no change in lipids — the original proof of concept.

   Read it asExpensive injectable with an increased fatal-infection signal. Never adopted for cardiovascular prevention in practice.

   Strong

2. CIRT — low-dose methotrexate

   New England Journal of Medicine · 2019

   SupportsThat broad, non-specific immunosuppression does not reduce cardiovascular events.

   Strong

3. COLCOT (2019) and LoDoCo2 (NEJM 2020) — low-dose colchicine

   Two secondary-prevention outcome trials · 2019 and 2020

   SupportsThe positive colchicine case, and the regulatory approvals that followed it.

   Moderate

4. CLEAR SYNERGY / OASIS-9 — colchicine after myocardial infarction

   Jolly SS, d’Entremont MA, Lee SF, et al., New England Journal of Medicine 2025;392(7):633–642 · 2025

   SupportsThat the largest colchicine trial run — 7,062 patients, median 3 years — found no reduction in the composite of cardiovascular death, recurrent infarction, stroke or ischaemia-driven revascularisation, despite lowering CRP. More diarrhoea in the colchicine arm.

   Read it asThis is why the therapeutic claim on this site is graded Contested rather than Moderate.

   Strong

5. ZEUS — ziltivekimab, direct IL-6 inhibition

   Novo Nordisk headline results; trial design in JAMA Cardiology 2026;11(1):89–97 · Announced 31 July 2026

   SupportsThat in over 6,300 people with established cardiovascular disease, chronic kidney disease and hs-CRP ≥ 2 mg/L, hitting the IL-6 target as designed produced a hazard ratio for major adverse cardiovascular events of 0.99 (95% CI 0.88–1.11).

   Read it asCurrency warning. Headline results only at the time of writing; full publication was expected at a scientific meeting later in 2026, and HERMES and ARTEMIS read out in the first half of 2027. Re-check before relying on this.

   Strong

Statin tolerability and the nocebo effect

Listed as a set because no single one of these settles it, and because the clinical pathway lists a long range of atypical presentations that would read as alarming without these alongside.

1. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis

   Cholesterol Treatment Trialists’ Collaboration, Lancet 2022;400(10355):832–845 · 2022

   Supports19 double-blind placebo-controlled trials, 123,940 participants, weighted median 4.3 years. Muscle pain or weakness in 27.1% on statin versus 26.6% on placebo (RR 1.03, 1.01–1.06). Year one RR 1.07 with an absolute excess of 11 events per 1,000 person-years, giving roughly one in fifteen reports attributable to the drug. No significant excess after year one.

   Read it asThis measures muscle symptoms in trial populations, which under-represent the very elderly, the frail, and people with multiple interacting medicines. It does not address rare severe myopathy, which is real and separately documented.

   Strong

2. SAMSON — Self-Assessment Method for Statin side-effects Or Nocebo

   Howard JP et al., NEJM 2020;383:2182–2184 and JACC 2021;78(12):1210–22 · 2020–21

   SupportsN-of-1 crossover in 60 patients who had already stopped statins for side effects. Symptom scores 16.3 on atorvastatin, 15.4 on placebo, substantially lower with no tablet at all. Nocebo ratio 90%. Half restarted a statin successfully afterwards.

   Read it asThe no-tablet periods are what distinguish this trial: they show placebo symptoms were actively produced by taking a tablet rather than being background symptoms. Small, and participants self-selected by agreeing to rechallenge.

   Strong

3. StatinWISE — statin treatment and muscle symptoms: series of randomised placebo-controlled n-of-1 trials

   Herrett E et al., BMJ 2021;372:n135 · 2021

   SupportsThe UK primary-care replication. Mean difference in symptom score between atorvastatin 20 mg and placebo −0.11 (95% CI −0.36 to 0.14). Two-thirds resumed the statin or intended to.

   Strong

4. ASCOT-LLA blinded versus non-blind phases

   Lancet 2017;389:2473–81 · 2017

   SupportsThat excess muscle-related adverse events appeared in the non-blind extension phase and not in the blinded randomised phase of the same trial, in the same patients — the cleanest natural experiment on this question.

   Strong

5. Statin-associated muscle symptoms: EAS Consensus Panel statement

   Stroes ES et al., European Heart Journal 2015;36:1012–1022 · 2015

   SupportsThe working definition of statin-associated muscle symptoms used to distinguish myalgia from myopathy, and the structured assessment and rechallenge approach the clinical pathway follows.

   Moderate

6. The objection to reading the N-of-1 trials too far

   Commentary literature, including Thompson PD · 2021–2026

   SupportsThat one-month treatment blocks may be too short for symptoms with delayed onset, that patients willing to rechallenge are self-selected toward milder cases, and that group means can conceal a genuinely affected minority.

   Read it asIncluded because the site does not present one side of a live methodological argument as settled. It does not change the recommended action — structured rechallenge is the right next step under either reading.

   Contested

Lipoprotein(a)

Mostly covered by the guidelines above, with three points worth sourcing separately.

1. The Lp(a)-lowering outcome trials

   Lp(a)HORIZON (pelacarsen, NCT04023552); OCEAN(a)-Outcomes (olpasiran, NCT05581303); ACCLAIM-Lp(a) (lepodisiran, NCT06292013); MOVE-Lp(a) (muvalaplin) · All phase 3, none reported as of August 2026

   SupportsThe pipeline table in the genetics chapter. Phase 2 lowering of roughly 80% for pelacarsen and above 90% for the RNA-silencing agents; Lp(a)HORIZON guided to a mid-2026 readout which passed without published results; OCEAN(a)-Outcomes expected to complete at the end of 2026.

   Read it asCurrency warning — the fastest-moving item on this site. None of the four is approved and none has shown that lowering Lp(a) reduces events. Phase 2 percentage reductions are surrogate endpoints and should be read as such: inflammation had the same shape of evidence before CLEAR SYNERGY and ZEUS. Check the trial registries before relying on anything here.

   Emerging

2. Residential radon, Lp(a) heritability and the once-in-a-lifetime position

   2019 ESC/EAS guidelines (Class IIa, Level C) and the 2026 ACC/AHA guideline · 2019 and 2026

   SupportsThat Lp(a) is roughly 70–90% genetically determined and should be measured at least once in adult life.

   Read it asRecent real-world cohorts report more within-person variation than the “once only” framing implies, particularly around menopause and with changing kidney function. Treat a single borderline result with less confidence than a single high or low one.

   Strong

Blood pressure and sleep

The two big rocks the site was missing until round 25.

1. Primary aldosteronism: prevalence, under-detection and screening

   Narrative reviews and cohort series 2015–2026, including the 2024 ESC hypertension guideline recommendation on aldosterone-to-renin ratio screening (Class IIa, Level B) · 2024–2026

   SupportsThat primary aldosteronism accounts for roughly 5–10% of all hypertension — a pooled figure near 9% in unselected hypertensive populations — rising to 20–30% in resistant hypertension and around 18% in young-onset disease; that only about 9–37% of confirmed cases have hypokalaemia; and that screening is heavily underused, with audits finding most eligible patients untested and a third or more of positive screens receiving no follow-up.

   Read it asPrevalence estimates vary widely with the diagnostic criteria used — one 2026 comparison found prevalence in the same cohort rising from 8.8% to 16.1% purely by moving from 2016 to 2025 Endocrine Society criteria. So the range quoted on this site is a range on purpose. Graded Moderate: the under-detection finding is consistent across settings, the exact prevalence is not.

   Moderate

2. NICE NG136 — Hypertension in adults: diagnosis and management

   National Institute for Health and Care Excellence · 2019, amended 2022; visual summary last updated July 2025

   SupportsThe staging table and both target tables in the blood pressure chapter: stage 1 at clinic 140/90 with ABPM or home average 135/85; stage 2 at 160/100 with 150/95; targets below 140/90 under 80 and below 150/90 at 80 and over, with the corresponding home figures.

   Read it asABPM is the reference standard for diagnosis, with home monitoring where ABPM is unsuitable — a raised clinic reading alone is explicitly not a diagnosis. NICE also instructs clinical judgement in frailty and multimorbidity, which is not a footnote.

   Strong

3. Arm Position and Blood Pressure Readings: the ARMS crossover randomised clinical trial

   Liu S, Zhao D, Sabit A, Brady TM, et al., JAMA Internal Medicine · 7 October 2024

   SupportsThat against the guideline position — arm supported at heart height — a hand resting in the lap overestimates systolic by 3.9 mmHg and diastolic by 4.0, an arm unsupported at the side by 6.5 and 4.4, and systolic by about 9 mmHg in people who are already hypertensive.

   Read it as133 participants, crossover, so each acted as their own control. The authors note it may apply only to automated devices. The variation around the mean was substantial, which matters: this is a systematic bias, not a fixed correction you can subtract.

   Strong

4. Sleep regularity is a stronger predictor of mortality risk than sleep duration

   Windred DP, Burns AC, Lane JM, Saxena R, Rutter MK, Cain SW, Phillips AJK, Sleep 2024;47(1):zsad253 · 2024

   SupportsThe regularity section of the sleep chapter: Sleep Regularity Index from over 10 million hours of accelerometry in 60,977 UK Biobank participants; the top four quintiles had 20–48% lower all-cause mortality, 16–39% lower cancer mortality and 22–57% lower cardiometabolic mortality against the least regular quintile, with regularity outperforming duration.

   Read it asObservational, one cohort, older and healthier and less ethnically diverse than the UK as a whole, with one week of accelerometry standing in for lifetime habit. Irregular sleep travels with shift work, illness, caring and poverty; adjustment does not fully remove those. Graded Moderate for that reason, and because the site does not upgrade a single cohort however large.

   Moderate

Alcohol

The observational and genetic literatures disagree here, so both are listed. The alcohol chapter says which it weights and why.

1. UK Chief Medical Officers’ Low Risk Drinking Guidelines, and the Guidelines Development Group report

   UK Chief Medical Officers · 2016, current

   SupportsThe 14-unit weekly guideline for both sexes, spread over three or more days; the UK unit as 10 ml / 8 g of pure alcohol; and the removal of the cardioprotection claim.

   Read it asThe 14-unit figure is the modelled point at which lifetime risk of dying from an alcohol-related cause reaches about 1%. The GDG states explicitly that these are guidelines for low-risk rather than safe drinking, and that risk continues to fall below the guideline. Quoting 14 units as a safety threshold misrepresents the source.

   Strong

2. Alcohol consumption and the risk of all-cause and cause-specific mortality — a linear and nonlinear Mendelian randomization study

   Kassaw NA, Zhou A, Mulugeta A, Lee SH, Burgess S, Hyppönen E, International Journal of Epidemiology 2024;53(2):dyae046 · 2024

   SupportsThat per additional unit (8 g) per day of genetically predicted intake the odds ratio was 1.27 for all-cause mortality, 1.30 for cardiovascular disease and 1.20 for cancer, with a linear relationship and no protective benefit at modest intake. 278,093 white-British UK Biobank participants; non-linear analysis used the doubly-ranked method and found no support for a J-shape.

   Read it asMendelian randomisation removes the sick-quitter problem and reverse causation but has its own assumptions — principally that the variants act on outcomes only through drinking. Non-linear MR methods are also newer and less settled than the linear form.

   Strong

3. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data

   Holmes MV, Dale CE, Zuccolo L, et al., BMJ 2014;349:g4164 · 2014

   SupportsThe earlier and more specific finding for coronary heart disease: no evidence of reduced risk at low intake once the genetic design removes confounding.

   Strong

4. The observational case that a protective effect is real

   Carr et al. 2024 and reviews weighting the cohort literature, including the European Heart Network report · 2024–25

   SupportsThat among 95 cohort and 27 case-control studies, most judged to have handled reverse causation adequately, a protective association with ischaemic heart disease persists in men, maximal around 20 g of ethanol daily.

   Read it asListed because the site does not present a live disagreement as settled. The dispute is about how much weight observational data retain once genetic data point the other way. This site weights the genetic evidence more heavily, consistently with how it treats lipids, and the chapter says so.

   Contested

5. Alcohol consumption — IARC Group 1 carcinogen classification, and the CMO review’s absolute risk figures

   International Agency for Research on Cancer; UK CMO Alcohol Guidelines Review · IARC classification long-standing; CMO review 2016

   SupportsCausal links to cancers of the mouth, throat, oesophagus, larynx, liver, colon and rectum, and breast; and the oesophageal cancer figures for men of roughly 6 per 1,000 in abstainers, 13 per 1,000 within the guideline and 25 per 1,000 at 14–35 units weekly.

   Read it asGroup 1 describes the strength of evidence that something causes cancer in humans, not the size of the risk. Reading it as “as dangerous as asbestos” is the standard misinterpretation and the chapter guards against it.

   Strong

Meal timing and time-restricted eating

1. TREAT (2020) and the 2022 randomised trial of time-restricted eating with calorie restriction

   TREAT, JAMA Internal Medicine 2020; and a randomised trial in the New England Journal of Medicine 2022 · 2020 and 2022

   SupportsThe Contested grade on the claim that time-restricted eating improves metabolic markers beyond the effect of eating less. TREAT found no significant benefit against a control eating pattern; the 2022 trial found time restriction added nothing to calorie restriction, with improvements in both arms tracking weight change.

   Read it asThese do not show TRE is useless — a rule about when is easier to follow than a rule about how much for some people, which is a real benefit. They show that an effect of timing independent of intake is unproven, which is the claim usually made for it.

   Contested

Fatty liver disease

The evidence behind the MASLD chapter.

1. EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD

   Journal of Hepatology · 2024

   SupportsThe two-step pathway: FIB-4 under 1.3 as a rule-out, 1.3–2.67 as indeterminate requiring elastography or ELF, 2.67 and above prompting referral; and the alternative of a year of intensified cardiometabolic management before retesting in the indeterminate band.

   Read it asFIB-4’s negative predictive value is around 90% and its positive predictive value is poor — which is the design, not a flaw, but it means a raised score is a trigger for a second test rather than a diagnosis.

   Strong

2. Age thresholds and FIB-4 performance

   McPherson et al. and subsequent validation work; summarised in AASLD and ADA guidance · 2017–2025

   SupportsThat in people over 65 the lower FIB-4 threshold should be around 2.0 rather than 1.3, and that below about 35 FIB-4 performs poorly enough that elastography is the better first test.

   Read it asAge is a term in the FIB-4 formula, so the score drifts upward with age independently of the liver. Meta-analyses also report meaningful heterogeneity in FIB-4 performance across populations, so these thresholds are conventions with good support rather than fixed constants.

   Moderate

3. Discordance between FIB-4 and liver stiffness measurement

   Systematic reviews and meta-analyses of non-invasive tests in MASLD · 2025–2026

   SupportsThat up to about 30% of patients have discordant FIB-4 and elastography results, with liver stiffness generally the better reflection of true fibrosis stage.

   Moderate

4. MAESTRO-NASH — resmetirom in MASH with liver fibrosis

   Harrison SA, Bedossa P, Guy CD, et al., New England Journal of Medicine 2024;390:497–509 · 2024

   SupportsThat roughly 26–30% achieved MASH resolution without worsening fibrosis at 12 months against about 10% on placebo, with fibrosis improvement also more frequent. Basis for FDA accelerated approval in March 2024 and subsequently MHRA authorisation.

   Read it asHistological surrogate endpoint. The trial measured what the biopsy looked like, not whether people avoided cirrhosis, transplant or death. Accelerated approval is explicitly conditional on confirmatory outcome data. Graded Moderate for that reason despite being a large positive phase 3.

   Moderate

5. ESSENCE — semaglutide in MASH with F2–F3 fibrosis

   Phase 3 trial, part 1 at 72 weeks · 2025–2026

   SupportsMASH resolution without worsening fibrosis in about 63% against roughly 34% on placebo, and fibrosis improvement in about 37% against 22.5%. Basis for FDA and then MHRA approval for MASH with moderate-to-advanced fibrosis.

   Read it asSame surrogate caveat. Part 2 of the trial, which carries the clinical outcome endpoints, runs to 2029. Both UK approvals also precede a NICE technology appraisal, so authorisation is not yet NHS availability.

   Moderate

6. Cardiovascular disease as the leading cause of death in MASLD

   Consistent finding across cohort literature and current review syntheses · ongoing

   SupportsThe framing of the chapter: that the commonest cause of death in fatty liver disease is cardiovascular rather than hepatic, and that a MASLD diagnosis should raise the estimate of cardiovascular risk.

   Strong

Inherited cardiac conditions

1. NICE CG71 — Familial hypercholesterolaemia: identification and management

   National Institute for Health and Care Excellence · 2008, updated 2017

   SupportsFH prevalence around 1 in 250, the case for cascade testing of first-degree relatives, and the Simon Broome criteria referenced in the clinical pathway.

   Read it asThe under-diagnosis figure is the point: most people with FH in the UK are not identified, and cascade testing from a known case is the highest-yield step available in preventive cardiology.

   Strong

2. Hypertrophic cardiomyopathy and the inherited arrhythmia syndromes

   Standard cardiology reference sources and UK inherited cardiac conditions service practice · current

   SupportsHCM affecting roughly 1 in 500 and being among the commonest causes of sudden cardiac death in the young; long QT at roughly 1 in 2,000; and that assessment is usually ECG and echocardiography with genetic testing following a finding rather than replacing it.

   Read it asPopulation screening is not recommended anywhere, and the site says so: these conditions are uncommon, ECG interpretation in young athletic hearts generates false positives, and the consequences of a wrong label are substantial. A negative genetic test also does not exclude the condition.

   Strong

Diet and food

1. Re-evaluation of the risks to public health from bisphenol A in foodstuffs

   EFSA Panel on Food Contact Materials, Enzymes and Processing Aids · April 2023

   SupportsThe tolerable daily intake for BPA cut from 4 µg/kg bw/day to 0.2 ng/kg bw/day, about a 20,000-fold reduction, and the subsequent EU ban on BPA in food contact materials (Regulation 2024/3190) in force from 20 January 2025.

   Read it asGraded Contested deliberately. The European Medicines Agency and Germany’s BfR filed diverging opinions, and the UK Committee on Toxicity did not adopt the new TDI, judging the weight-of-evidence analysis insufficient. So UK and EU positions differ and the EU ban does not cover UK-market products. Two competent bodies, the same toxicology, different conclusions.

   Contested

2. Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses

   Lane MM et al., BMJ 2024;384:e077310 · 28 February 2024

   SupportsThe ultra-processed food card on the exposures chapter and the UPF framing in the eating guide. 45 pooled analyses from 14 reviews, 9,888,373 participants, 32 adverse outcomes.

   Read it asObservational throughout. The authors graded only a subset as convincing, and the exposure measure — food frequency questionnaires and recall — is the weak link. Strong for “this association is real and consistent”, not for any specific mechanism.

   Strong

Obstetric emergencies and tocolysis

1. NICE NG25 — Preterm labour and birth

   National Institute for Health and Care Excellence · 2015, updated

   SupportsThat nifedipine is first-line tocolysis in the UK with atosiban where nifedipine is contraindicated, and that the purpose of tocolysis is to buy time for antenatal corticosteroids, magnesium sulfate where indicated, and transfer — not to prevent preterm birth.

   Read it asTransdermal glyceryl trinitrate does not appear in NG25. The chapter says so explicitly rather than implying guideline status.

   Strong

2. Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis

   Individual participant data meta-analysis of randomised trials comparing nifedipine with atosiban for 48 hours of tocolysis at 24+0 to 34+0 weeks · 2022

   SupportsThe comparable pair in the prolongation table on the preterm labour chapter: nifedipine 18 days to delivery against atosiban 10 days (HR 0.83, 96% CI 0.69–0.99), with NICU admission less frequent after nifedipine (46% against 59%).

   Read it asAnd the finding the chapter leans on hardest. Despite nearly twice the prolongation, there was no difference in the composite of neonatal morbidity and perinatal mortality, and neonatal mortality was numerically higher in the nifedipine arm (OR 1.4, 95% CI 0.60–3.4) — not significant, and flagged by the authors as warranting further investigation. This is the clearest available demonstration that days gained is a surrogate rather than the outcome, and it is why the chapter is organised around what the days are spent on. Individual participant data is the strongest design in this literature, which is why these two figures are the only directly comparable pair in the table.

   Strong

3. Pregnancy prolongation figures for nifedipine and magnesium sulfate

   Cochrane maintenance-tocolysis estimate; Sayin et al. 2004; a randomised maintenance trial reporting median 20 days (IQR 2.5–51); and a head-to-head against magnesium sulfate reporting 6.1 against 4.6 days · 2004–2017

   SupportsThe lowest and highest reported averages in the table: 5.4 days from Cochrane maintenance data and 26.7 days from Sayin, with an interquartile range of 2.5 to 51 days from one randomised trial giving a better sense of the spread than any average.

   Read it asThese figures are not measuring the same quantity. Some report days from trial entry to delivery, some prolongation from the start of treatment, some maintenance rather than acute tocolysis. The chapter shows the span as a range of study averages and states that comparing one agent’s bar against another is weaker than it looks — which is why indomethacin and betamimetics are left without a bar rather than given an invented number.

   Moderate

4. How long transdermal GTN prolongs pregnancy — the duration literature

   Lees C et al., Lancet 1994;343:1325–1326; Lees CC et al., Obstet Gynecol 1999;94:403–408; Bisits A et al., Randomized Nitric Oxide Tocolysis Trial (RNOTT), Am J Obstet Gynecol 2004;191:683–690; systematic review and meta-analysis, Am J Obstet Gynecol 2013; Gaikwad V, Gaikwad S, Tiwari P, Cureus 2024 · 1994–2024

   SupportsThe duration panel in the preterm labour chapter: a mean prolongation of 34 days in the original 1994 consecutive series of 13 women and 20 episodes, all of which responded; a mean of about 9.5 days in the GTN arm of RNOTT; a mean of 28.6 days in a 100-woman retrospective cohort at 27–35 weeks, with 90% reaching 48 hours and contractions inhibited in 92%; and gestation prolonged by 74% of the time remaining to 37 weeks in the 1999 multicentre trial, identical to ritodrine but with fewer preterm deliveries and fewer side effects.

   Read it asThe apparent contradiction is real and resolvable. Continuous measures — mean days gained, mean gestational age at delivery — consistently favour GTN. Binary endpoints against placebo — delivery within 48 hours, delivery before 28, 34 or 37 weeks — do not reach significance in the 2013 pooled analysis. An agent can move an average substantially while failing to shift a threshold most participants in both arms were going to cross or avoid regardless, and small trials are underpowered for the harder endpoint. The 2013 review also found GTN superior to β2-agonists for birth before 34 and 37 weeks, NICU admission and ventilation, and no different from nifedipine or magnesium. The retrospective 28.6-day figure is the weakest design in the group and should not be read as the expected result. On the application site: published series specify the anterior abdominal wall — for example Parveen et al. 2012, 65 women at 28–34 weeks with a 5 mg/12 h patch applied there — which is why the protocol uses the abdomen. That is a matter of following the studied route and of practicality, not of local drug action: transdermal GTN is a systemic delivery system, and the myometrium is centimetres deep behind fat, fascia and peritoneum even at term, well beyond the depth at which topical application produces meaningful tissue concentrations. GTN’s genuine local effects — venodilation for cannulation, anal fissure, Raynaud’s — all involve targets millimetres below the skin.

   Moderate

5. Tocolytics for delaying preterm birth: a network meta-analysis

   Wilson A, Hodgetts-Morton VA, Marson EJ, et al. Cochrane Database of Systematic Reviews 2022;8(8):CD014978 · 10 August 2022

   SupportsThe comparison in the preterm labour chapter: that all tocolytic classes — betamimetics, calcium channel blockers, magnesium sulfate, oxytocin receptor antagonists and nitric oxide donors — and their combinations are probably or possibly effective at delaying birth by 48 hours and 7 days against placebo or no treatment; that effects on neonatal and perinatal mortality and on maternal and neonatal infection were uncertain; and that betamimetics and combinations were the most likely to have treatment stopped for adverse effects. Betamimetic maternal harms against placebo: dyspnoea RR 12.09, palpitations RR 7.39, tachycardia RR 3.01, vomiting RR 1.91, headache RR 1.91. Nitric oxide donors: birthweight higher by a mean 425.53 g, fewer neonates under 2500 g at RR 0.40, gestational age 1.35 weeks more advanced — all low certainty. Combinations: fewer under 2500 g at RR 0.74, low certainty.

   Read it asThe load-bearing finding is the negative one. Delay is a surrogate; the outcome that matters was not established for any class. That is why the chapter frames tocolysis as instrumental — it creates the window for corticosteroids, magnesium neuroprotection and transfer, which are the interventions with outcome evidence. The nitric oxide donor signals are the most striking in the review and are low certainty on small numbers; they are reported on the page with that caveat attached rather than as a reason to prefer GTN.

   Strong

6. Comparison between nitroglycerin dermal patch and nifedipine for treatment of preterm labor

   Kashanian M, Zamen Z, Sheikhansari N, Journal of Perinatology 2014;34:683–687 · 2014

   SupportsThe adverse-effect comparison in the GTN protocol: headache comparable between GTN and nifedipine at around 28% each, hypotension roughly 25% against 28%, and nausea and tachycardia more common with GTN. Direction supported by a 2025 meta-analysis and the NICHD tocolytic synthesis.

   Read it asSingle randomised comparison, modest size. The figures are quoted as the source of a comparison rather than as population rates, and the protocol names the study on the page so the numbers can be weighed and superseded.

   Moderate

7. Head injury observation, delayed bleeding, and what detects it

   NICE NG232 on head injury assessment and early management; UK and Australian mild head injury pathways; case series and reviews of delayed subdural haematoma in anticoagulated patients; and the 2024 multidisciplinary chronic subdural haematoma guidelines · 2023–2026

   SupportsThe monitoring section in the head injury chapter: a responsible adult staying for 24 hours with the ability to rouse them; that a normal scan with a Glasgow Coma Scale below 15 at 24 hours prompts further imaging; the two-to-three-week window for a chronic subdural haematoma with its higher risk in older, anticoagulated and heavy-drinking patients; the subtle late signs including personality change, slowed thinking, unsteadiness and new incontinence; and that abnormal alertness, behaviour and cognition detect subtle brain injury better than the Glasgow Coma Scale.

   Read it asTwo points the chapter leans on. Anticoagulated patients can develop a significant haematoma after a normal initial scan — described at 48 hours in reported cases — which is why any head impact on an anticoagulant warrants assessment regardless of appearance. And pupil asymmetry is a late sign reflecting brainstem pressure, with roughly one person in five having benign anisocoria at baseline; the chapter therefore treats pupils as confirmatory rather than as a detection tool, and says that if pupils are what finally prompts the 999 call, the call is late.

   Strong

8. Aminoglycoside ototoxicity and the m.1555A>G variant

   NICE NG195 on neonatal infection; the PALOH implementation trial and subsequent UK national survey of neonatal first-line antibiotics; CPIC 2021 guidance; and NICE early value assessment of the Genedrive MT-RNR1 test · 2019–2026

   SupportsThe gentamicin section in the preterm labour chapter: that NICE recommends benzylpenicillin plus gentamicin first-line for suspected early-onset neonatal sepsis, chosen for its narrow spectrum rather than superior efficacy; that roughly 1 in 500 people carry m.1555A>G and can suffer profound irreversible sensorineural deafness from a standard exposure, equating to about 1,200 affected infants born annually in England and Wales and an estimated 120 a year exposed unnecessarily; that a point-of-care test detects the variant from a buccal swab in about 26 minutes and was implemented without delaying antibiotics, with only 3.3% of admissions untested; and that a cephalosporin-based regimen is the alternative in carriers.

   Read it asThe framing matters in both directions. Gentamicin is not a drug to avoid by default — it is UK first-line therapy and the alternative regimens drive more resistance. But for carriers the risk is not small, it is a single exposure away from permanent deafness, and CPIC advises avoidance unless infection severity and the absence of a safe alternative outweigh it. Because inheritance is mitochondrial, maternal genotype predicts the infant’s: one series found the variant in every mother of an affected child and in none of nearly 3,000 mothers of unaffected infants, which is the basis for the proposal to test mothers during preterm labour. Not routine UK practice, and a maternal-line family history of hearing loss is the available clinical flag.

   Strong

9. Newborn resuscitation and support of transition of infants at birth — thermal care

   Resuscitation Council UK Guidelines 2025; with UK regional prehospital neonatal frameworks · 2025

   SupportsThe gestation split in birth before arrival: at or near term, dry, hat, skin to skin. Preterm, and roughly below 32 weeks, dry the head only and put the body into a clear polyethylene bag or wrap without drying, head out, because evaporative heat loss outpaces towelling. Plus the fallbacks — if no bag can be found quickly, dry gently and wrap in a warm towel rather than delay, and a bag is still worth using on a baby already dried.

   Read it asThe plastic-wrap technique is supported by randomised trials and Cochrane review for preventing hypothermia in preterm and low-birth-weight infants, and hypothermia at admission is independently associated with mortality. Note the interaction: combining a bag with an exothermic mattress has produced admission hyperthermia in some series, so it is one measure, not a stack.

   Strong

10. Transdermal glyceryl trinitrate as a tocolytic

    Lees C et al., Lancet 1994;343:1325–1326; Lees et al. 1999 comparison with ritodrine; Smith GN et al., Canadian Preterm Labour Nitroglycerin Trial, Am J Obstet Gynecol 2007;196:37.e1–8; systematic review and meta-analysis, Am J Obstet Gynecol 2013; Duckitt K, Thornton S, Cochrane review of nitric oxide donors · 1994–2024

    SupportsThat GTN measurably reduces uterine contractility, that the original series arrested preterm labour in a small consecutive cohort, and that against ritodrine it achieved similar acute tocolysis with a lower overall preterm delivery rate and fewer side effects.

    Read it asGraded Contested and not Moderate. The effect on contractility is not in dispute; the clinical trial evidence is small, mixed, and has not persuaded UK guideline committees. More recent comparisons have found oral nifedipine superior on both efficacy and side-effect profile. The chapter presents the counterweight alongside the supportive trials rather than after them. Headache is very common and often severe; hypotension and transient tachycardia occur; contraindications include hypotension, nitrate sensitivity, glaucoma, raised intracranial pressure and obstructive hypertrophic cardiomyopathy. This is a prescribing decision, and the chapter frames any use as pre-arranged with an obstetric team and as a bridge to hospital rather than an alternative to it.

    Contested

Longevity, healthspan and environmental exposures

1. Healthy life expectancy, UK: between 2011 to 2013 and 2022 to 2024

   Office for National Statistics · Released 19 February 2026

   SupportsThe lifespan-versus-healthspan table on the longevity Essentials: 60.7 years in good health for men and 60.9 for women, decreases of 1.8 and 2.5 years against 2019–21, and the lowest since the series began.

   Read it as“Good health” here is self-reported in a survey, not clinically assessed. It measures something real but subjective, and the deprivation gap of roughly twenty years dwarfs anything individual behaviour explains.

   Strong

2. National life tables, UK

   Office for National Statistics · 2022–24 data

   SupportsLife expectancy at birth of 79.1 years for men and 83.0 for women.

   Strong

3. UK PM2.5 sources and targets — domestic burning as the largest single source

   Defra National Atmospheric Emissions Inventory, 2023 emissions; House of Commons Library briefing CBP-10543, Controls on domestic wood-burning and solid fuel use in England; Environment Act 2021 statutory targets and the Environmental Improvement Plan; WHO Global Air Quality Guidelines 2021 · 2021–2026

   SupportsThe air pollution chapter: that domestic burning of wood and solid fuel accounted for roughly a fifth of UK PM2.5 emissions in 2023, making it one of the two largest sources — similar in size to road transport once brake, tyre and road wear are included, and more than twice road transport's exhaust component, which is the like-for-like combustion comparison. Emissions rose steeply through the 2010s and have fallen somewhat since 2020, leaving it the only major source substantially higher than a decade ago; that England’s statutory target is an annual mean of 10 µg/m³ by 2040 with an interim target of 12 by 2028 and a 35% reduction in population exposure against 2018, against a WHO guideline of 5 µg/m³; that average exposure in England fell about 54% between 2003 and 2023 with two-fifths of that fall occurring in 2020; and that the most deprived fifth of areas experienced about 8% higher PM2.5 than the least deprived in 2023, with no clear narrowing over two decades.

   Read it asThe chapter is deliberately blunter about wood burners than about anything else on the register, and the justification is arithmetic rather than taste: it is one of the two largest sources, it is the only one substantially higher than a decade ago, survey evidence indicates it is supplementary rather than primary heating for most owners, and the exposure falls substantially on neighbours. It also states plainly that Ecodesign and Defra-exempt labels mean lower emissions than an open fire, not low emissions. The chapter separately insists that the cardiovascular benefit of outdoor exercise exceeds the harm of the pollution breathed during it at realistic UK exposures, because discouraging activity is the commonest way this subject causes net harm. Local shares vary widely and city-level figures differ from the national inventory; the chapter uses the national figure and says shares are higher in some places.

   Strong

4. Ultra-processed food — the umbrella review and the metabolic ward trial

   Lane MM et al., Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses, BMJ 2024;384:e077310; Hall KD et al., Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain, Cell Metabolism 2019;30(1):67–77 · 2019 and 2024

   SupportsThe ultra-processed food chapter: the umbrella review of 45 meta-analyses covering approximately 9.9 million participants, reporting associations with 32 adverse health outcomes including roughly 50% higher cardiovascular mortality and about 21% higher all-cause mortality. And the Hall randomised crossover trial: 20 adults resident on a metabolic ward for four weeks, two weeks on each of an ultra-processed and an unprocessed diet matched for presented calories, sugar, fat, fibre and macronutrients, eating ad libitum — consuming approximately 500 kcal per day more on the ultra-processed arm, with weight gained on that arm and lost on the other.

   Read it asThe chapter argues that the category is weak and that the site should say so. NOVA sorts by production method rather than composition, so wholemeal supermarket bread, baked beans, plain yoghurt and most infant formula sit alongside cola and crisps; independent coders reproduce the classification imperfectly; and ultra-processed intake correlates strongly with free sugar, salt, energy density, low fibre and deprivation, making the processing effect hard to isolate. UK advisory opinion is now named on the page: the Scientific Advisory Committee on Nutrition's position statement on processed foods and health (July 2023) and its rapid evidence update (2025), which describe the associations as concerning while setting out NOVA's limitations and the likelihood of residual confounding, and make no ultra-processed-specific dietary recommendation. SACN's own critique of the Hall trial matches the caveats already on the page. The chapter resolves the tension by replacing the category with its underlying properties — eating rate, energy density, fibre and protein content, liquid calories — which sort the borderline foods correctly where NOVA does not.

   Strong

5. Bisphenol A in food contact materials — the EU ban and the Great Britain position

   Commission Regulation (EU) 2024/3190, published 31 December 2024, in force 20 January 2025, amending Regulation (EU) No 10/2011 and repealing Regulation (EU) 2018/213; European Commission implementation guidance, December 2025; and the UK Government publication BPA in food contact materials: EU rules and UK implications, with the FSA and Food Standards Scotland consultation response · 2024–2026

   SupportsSection 3 of the non-stick and food contact chapter: that the EU has prohibited BPA in food contact plastics, coatings, varnishes, printing inks, adhesives, silicones, rubber and ion-exchange resins, with the previous specific migration limit of 0.05 mg/kg repealed on entry into force and an 18-month transition, so the prohibition has applied since 20 July 2026, with later dates for repeat-use articles (2027) and professional equipment (2028); that the ban also covers bisphenol S, bisphenol AF and other harmonised-classified bisphenols, restricting the substitution route, though with conditional derogations for some existing uses; that paper and board are outside the ban unless combined with regulated materials; that it applies in Northern Ireland under the Windsor Framework; and that in Great Britain the FSA and FSS have consulted and stated an intention to introduce restrictions subject to the policy and legislative process, but had not legislated as at August 2026, with reporting suggesting domestic legislation is unlikely before mid-2027 and UK–EU sanitary and phytosanitary negotiations a wildcard. The divergence is therefore live rather than prospective.

   Read it asThis is the second Great Britain / Northern Ireland divergence recorded on this site, the other being fragrance allergen labelling, and the chapter draws the connection explicitly: “UK rules” is no longer a single answer for consumer chemistry. The practical consequence stated is narrow and checkable — a “BPA-free” claim is a weaker claim in GB than in the EU, because the substitute bisphenols are restricted there and not here. The chapter deliberately declines to turn this into alarm about tinned food: exposure has been falling through voluntary reformulation, the tolerable intake is a matter of genuine expert disagreement, and the nutritional cost of avoiding tinned pulses and fish would be real. The GB position is actively moving and should be rechecked.

   Strong

6. Microplastics and nanoplastics in atheroma — and the contamination objection

   Marfella R, Prattichizzo F, Sardu C, et al. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events, New England Journal of Medicine 2024;390(10):900–910, doi:10.1056/NEJMoa2309822; with the published correspondence on sample contamination, NEJM doi:10.1056/NEJMc2404154 · 2024

   SupportsSection 1 of the microplastics chapter: a prospective multicentre observational study of 257 patients undergoing carotid endarterectomy for asymptomatic disease, detecting micro- and nanoplastics — principally polyethylene and polyvinyl chloride — in the excised plaque of 150 (58%) by pyrolysis gas chromatography–mass spectrometry, stable isotope analysis and electron microscopy. Over a median 34 months, the composite of myocardial infarction, stroke or death from any cause occurred in 30 of 150 with particles against 8 of 107 without — hazard ratio 4.53, 95% CI 2.00 to 10.27, p < 0.001. Plaque containing particles showed higher IL-18, IL-1β and CRP.

   Read it asThe published objection is given equal weight on the page, because it is not a quibble. Correspondence in the same journal notes that no pre-analytical anti-contamination procedures were described beyond the use of glass tubes, and no blank samples were taken from the operating theatre — and that a surgical environment contains abundant polyethylene and PVC, precisely the two polymers reported. If the particles originated there rather than in the patient, the finding does not stand. The authors dispute this and it is unresolved. The chapter also declines to repeat the widely quoted “credit card a week” ingestion figure, which derives from a modelling exercise rather than a measurement and has been criticised sharply, and treats organ-burden mass estimates as provisional given that quantification methods are still being validated and contamination is a pervasive problem across the field. The argument it lands on is that the additives plastics carry — bisphenols, phthalates, PFAS — have decades of human epidemiology where the particles have one contested study, and that the same practical actions reduce both, so nobody needs to resolve the science to act.

   Emerging

7. Fragrance allergen labelling — the EU expansion and the Great Britain divergence

   Commission Regulation (EU) 2023/1545 of 26 July 2023, amending Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens, in force 16 August 2023, based on SCCS Opinion 1459/11; UK Cosmetics Regulation as retained and enforced by the Office for Product Safety and Standards; Windsor Framework arrangements for Northern Ireland · 2023, first deadline 31 July 2026

   SupportsThe labelling section of the fragrance and cleaning products chapter: that a perfume may be declared as the single word parfum, with only recognised contact allergens named separately; that Regulation (EU) 2023/1545 expanded that list from 24–26 substances to about 82, including several essential oils named as whole substances; that the declaration thresholds are 0.001% in leave-on and 0.01% in rinse-off products; and that the transition dates are 31 July 2026 for placing new products on the market and 31 July 2028 for selling through existing stock. That Great Britain has not adopted the expansion and still runs the original list of 26, while Northern Ireland follows EU cosmetics law.

   Read it asThis is a live divergence inside the United Kingdom, not a historical Brexit point, and it has practical consequences a shopper can see: the same product may carry a longer ingredients list in Belfast than in Birmingham, and the longer one is more informative. The chapter also makes the point that none of this covers household cleaning products at all — detergents, surface sprays, fabric conditioners and air fresheners fall under detergents and chemicals law rather than cosmetics law, where the labelling duty is narrower, so the cupboard containing the most fragrance carries the least disclosure. Any change to the GB position would come through OPSS; the position stated is as at August 2026 and should be rechecked.

   Strong

8. Flame retardants in UK furniture, and the 2025 exclusion of children's products

   Furniture and Furnishings (Fire) (Safety) Regulations 1988; Furniture and Furnishings (Fire) (Safety) (Amendment) Regulations 2025, in force 30 October 2025; House of Lords Library briefing on fire safety regulation reform, citing a UK Research and Innovation convened scientific group; House of Commons Environmental Audit Committee, Toxic chemicals in everyday life (2019); OPSS and Department for Business and Trade consultation on further reform · 1988–2026

   SupportsThe flame retardant section of the fragrance and cleaning chapter: that the 1988 regulations require an open-flame ignition test which manufacturers have largely satisfied by adding chemical flame retardants, and that a UKRI-convened scientific group has observed the UK has some of the highest usage of flame retardants in the world, in large part because of that test; that additive flame retardants migrate from foam and textile into household dust, which is the exposure route rather than skin contact with fabric; and that the Amendment Regulations 2025 removed a list of baby and children's products — cot mattresses under 170 cm, pram sacks, car seat inserts and similar — from the scope of the 1988 regulations, on the explicit basis that for those products the chemical exposure risk is greater than the fire risk.

   Read it asThis entry corrects a common claim rather than supporting it. The advice to wash new clothes “because of fire retardants” is aimed at the wrong product: ordinary UK clothing is not flame-retarded, nightwear excepted. Washing new clothes remains sensible for a different reason — residual disperse dyes, a recognised cause of contact dermatitis, and formaldehyde-based crease-resist finishes. The substantial domestic flame retardant exposure is upholstered furniture, and it travels in dust, which makes small children on floors the most exposed group and makes damp-dusting and HEPA vacuuming the effective response. Further reform is under consultation, including a smoulder test and a requirement that manufacturers justify using chemical flame retardants at all, so this position is expected to move.

   Strong

9. Cleaning products, indoor air chemistry and respiratory outcomes

   Svanes Ø et al., Cleaning at Home and at Work in Relation to Lung Function Decline and Airway Obstruction, American Journal of Respiratory and Critical Care Medicine 2018;197(9):1157–1163 (ECRHS cohort); with the indoor air literature on terpene–ozone reaction chemistry and secondary organic aerosol formation, and occupational asthma surveillance data on quaternary ammonium compounds · 2018 and current

   SupportsSection 4 of the chapter: 6,230 adults across 22 European centres with lung function measured three times over more than 20 years, finding FEV₁ declines of 22.1 mL/year in women responsible for cleaning at home and 22.4 in occupational cleaners against 18.5 in non-cleaners — an excess of about 3.6 and 3.9 mL/year, with FVC excesses of about 4.3 and 7.1. The authors compared the occupational effect to somewhat less than 20 pack-years of smoking, a cumulative exposure. And section 3: that limonene and other terpenes react with indoor ozone to form formaldehyde and secondary organic aerosol, so exposure peaks after cleaning stops rather than during it.

   Read it asThe caveat the chapter insists on, because almost every repetition of this study omits it: Svanes found no faster decline in the FEV₁/FVC ratio and no accompanying excess of obstructive airway disease. It is a measurable loss of lung volume over two decades, not a demonstration that domestic cleaning causes COPD, and the smoking comparison is to 20 pack-years — a cumulative lifetime exposure — rather than to twenty a day, which is the form it is almost universally repeated in and a materially larger claim. An earlier version of this site reported the 22 mL/year total decline as though it were the excess attributable to cleaning, overstating the effect roughly sixfold; that is corrected. No effect was seen in men, though the number of male occupational cleaners was small. The design is observational. The chapter grades airway irritation and occupational asthma Strong and the systemic claims made about the same products at domestic exposure Emerging, because those rest largely on mechanism.

   Strong

10. Sunscreen — application quantity, UVA rating, and UK filter regulation

    ISO 24444 SPF test methodology (2 mg/cm² application); the UK and EU requirement that UVA-PF be at least one-third of the labelled SPF for the UVA circle; MHRA and SAG-CS reviews of homosalate and oxybenzone; and the behavioural literature on higher-SPF products and time spent in sun · current

    SupportsThe sunscreen chapter: that SPF is tested at 2 mg/cm² while real-world application is typically a quarter to a half of that, and that because the protection relationship is exponential rather than linear, applying half the tested thickness gives approximately the square root of the labelled SPF — so an SPF 50 applied at half thickness behaves like roughly SPF 7. That about 35 ml covers an adult body, and the two-finger measure covers face and neck. That the UVA circle is a floor (UVA-PF at least one-third of SPF) rather than a grade, while the star rating expresses UVA protection relative to SPF. That the EU restricted oxybenzone to 2.2% in body products in 2022 and the UK followed in January 2026, and that the UK reviewed homosalate separately and retained 10% across all product types where the EU cut it to 7.34% in face products. And that people given higher-SPF products stay out longer, which is the mechanism of the false-security effect.

    Read it asThe square-root approximation is a rule of thumb, not a physical law, and real products deviate from it — but it is directionally right and it is the single most useful thing a reader can take from the chapter, because it reframes “which sunscreen” as the less important question. The chapter also states plainly that demonstrated systemic absorption of filters is not demonstrated harm: the FDA maximal-usage studies crossed a screening threshold that triggers further toxicology rather than establishing toxicity, and no human harm signal has emerged. The restrictions are precautionary; the skin cancer risk from non-use is not.

    Strong

11. Bemotrizinol, bisoctrizole and the modern UV filters

    US FDA final order adding bemotrizinol to permitted sunscreen actives, 9 June 2026 (effective 9 August 2026, up to 6%); with BASF and DSM-Firmenich product information for Tinosorb S / Parsol Shield, Tinosorb M and Uvinul A Plus, and L’Oréal for Mexoryl 400 · 1999–2026

    SupportsThat bemotrizinol (bis-ethylhexyloxyphenol methoxyphenyl triazine, Tinosorb S, Parsol Shield) is a broad-spectrum, highly photostable filter that also stabilises avobenzone, in European use since about 1999, and was approved in the United States on 9 June 2026 — its first new sunscreen active in around 25 years, with products expected from August 2026. That bisoctrizole (Tinosorb M) is a different compound and remains unapproved in the United States, as do Uvinul A Plus (DHHB) and the Mexoryls.

    Read it asThe chapter frames this as American news rather than British news, because that is what it is: UK and EU consumers have had these filters for a quarter of a century, and the practical implication here is only that they are worth choosing. Bemotrizinol and bisoctrizole are routinely conflated — including in the source material this section was written from — and the chapter separates them explicitly. The FDA data supported bemotrizinol at concentrations up to 6% with absorption below the agency’s systemic-exposure threshold.

    Strong

12. Sun exposure beyond vitamin D — nitric oxide, and the MISS cohort mortality data

    Liu D, Feelisch M, Weller R and colleagues on cutaneous nitric oxide mobilisation; Lindqvist PG et al., Melanoma in Southern Sweden (MISS) cohort; Chowdhury R et al. pooled 25(OH)D analysis (~849,000 participants); Alfredsson L et al., Int J Environ Res Public Health 2020;17:5014 · 2013–2020

    SupportsThe extended sun card on the exposures chapter: that UVA mobilises nitrite and nitrate stored in skin into circulating nitric oxide, lowering blood pressure independently of vitamin D, with warmth and dietary nitrate excluded as explanations; that low 25(OH)D is strongly associated with cardiovascular, cancer and all-cause mortality while supplementation trials show no corresponding benefit — the signature of a marker rather than a mechanism; and that in the MISS cohort the lowest sun-exposure group had the highest mortality, with sun avoidance estimated as a risk factor of magnitude similar to smoking.

    Read it asRead the smoking comparison with care. It is observational, from a fair-skinned Nordic cohort in which sun-seeking also tracks affluence, holidays, outdoor activity and better baseline health, and reverse causation is plausible because unwell people go out less. The 2020 review that popularised the attributable-death figures is a position paper arguing a case, and its numbers derive from vitamin D association data whose own authors state that supplementation does not help. The nitric oxide mechanism is the better-supported part. None of it changes the melanoma evidence, and the chapter says so.

    Moderate

13. Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them

    Gray A, Read S, McGale P, Darby S, BMJ 2009;338:a3110 · 2009

    SupportsThat radon is associated with around 1,100 UK lung cancer deaths a year, 3.3% of the total, and that over 85% of them arise from concentrations below the 100 Bq/m³ action level. Mean UK home: 21 Bq/m³.

    Read it asThe sub-action-level finding is the one that changes behaviour, and it is why the advice on this site is to test rather than to check whether your area is designated.

    Strong

14. Residential radon and lung cancer: collaborative analysis of individual data from 13 European case-control studies

    Darby S et al., BMJ 2005 · 2005

    SupportsThe dose-response relationship itself: linear, no threshold, roughly 16% excess relative risk per 100 Bq/m³ after correction for measurement error, and multiplicative with smoking.

    Strong

15. Excess winter deaths and illness and the health risks associated with cold homes (NG6)

    National Institute for Health and Care Excellence, with the Marmot Review Team’s The Health Impacts of Cold Homes and Fuel Poverty · NG6 published 2015; Marmot review 2011

    SupportsThat England and Wales record on the order of twenty thousand excess winter deaths in an average year, that these are predominantly cardiovascular and respiratory rather than hypothermia, and the Marmot finding that excess winter deaths in the coldest quarter of housing ran at close to three times the rate of the warmest quarter.

    Read it asExcess winter mortality is a noisy measure: England and Wales recorded 18,200 in 2013/14 and around 49,000 in 2017/18, so any single year is a poor guide and the site quotes an order of magnitude rather than a figure. Attribution to cold housing specifically, as opposed to winter generally, is modelled rather than measured — which is why the exposure is graded Moderate.

    Moderate

16. WHO Housing and Health Guidelines — systematic review on the effect of indoor cold on health

    World Health Organization, incorporating Public Health England’s minimum home temperature review (Wookey, 2014) · 2018

    SupportsThe 18 °C minimum indoor temperature used on this site, and the finding that the certainty of evidence for warming a cold home to 18 °C reducing cardiovascular mortality and morbidity is moderate.

    Read it asThe site takes WHO’s own grading rather than upgrading it. The blood-pressure mechanism is well evidenced; randomised evidence on deaths does not exist and is unlikely to.

    Moderate

17. Updated mortality burden estimates attributable to air pollution

    Evangelopoulos D, Walton H — UK Health Security Agency, Chemical Hazards and Poisons Report issue 28 · 2022, for 2019 exposure

    SupportsThe estimate of 29,000–43,000 attributable deaths a year in UK adults aged 30 and over, from long-term PM2.5 and NO₂.

    Read it as“Attributable deaths” is a statistical construct — an equivalent number spread across a population, not a count of identifiable people. The range is wide because PM2.5 and NO₂ effects overlap by an amount that is still being quantified. The widely quoted single figure of 40,000 is a midpoint judgement, not a measurement.

    Moderate

Urinary infection and urinalysis

1. NICE NG109 — Urinary tract infection (lower): antimicrobial prescribing, with NG111, NG112 and NG113

   National Institute for Health and Care Excellence · 2018, updated 2025

   SupportsThe prescribing tables in the urinary infection chapter: nitrofurantoin as first choice with a 3-day course in non-pregnant women under 65 and 7 days in men; second choices of nitrofurantoin if not used first, pivmecillinam or fosfomycin; cefalexin in pregnancy at term or where nitrofurantoin is unsuitable; and the exclusions — nitrofurantoin avoided below an eGFR of 45 and at term in pregnancy because of neonatal haemolysis, trimethoprim contraindicated in the first trimester as a folate antagonist, and amoxicillin only on a sensitive culture. Also the nitrite and leukocyte decision table, and that a dipstick should not be used to diagnose urinary infection in people over 65 or with a catheter.

   Read it asThe point of the penicillin-allergy table is pivmecillinam. NICE offers it as a second choice, it is unfamiliar to many prescribers, and it is a beta-lactam — so it is the option most likely to be reached for by mistake in a penicillin-allergic patient. Nitrofurantoin, trimethoprim and fosfomycin are all structurally unrelated to penicillin and are the ones that survive. NICE also notes trimethoprim resistance is more likely with use in the previous 3 months and in older people in residential care, which is the group most likely to be given it blind.

   Strong

2. Multistix 10 SG reagent strips — pack insert, read times and interference

   Siemens Healthineers Multistix 10 SG product information and equivalent 10-parameter strip inserts; with standard urinalysis reference texts · current

   SupportsThe dipstick chapter: read times of 30 s for glucose and bilirubin, 40 s ketones, 45 s specific gravity, 60 s blood, pH, protein, urobilinogen and nitrite, and 120 s for leukocytes; that colour change on the leukocyte pad after 2 minutes is disregarded; the runover phenomenon in which acid buffer from the protein pad falsely lowers the pH reading if excess urine is not blotted; that any bilirubin is abnormal and the normal urobilinogen range is 0.2–1.0 mg/dL with 2.0 the transition; that the ketone pad measures acetoacetate rather than beta-hydroxybutyrate; that the blood pad detects peroxidase activity and so responds to myoglobin and to bacterial peroxidases; that leukocyte esterase detects neutrophils, eosinophils, basophils and monocytes but not lymphocytes; and the interference list — ascorbic acid above about 25 mg/dL causing false-negative nitrite, high specific gravity causing false-positive protein and false-negative glucose, blood and nitrite, cefalexin, tetracycline and high glucose lowering leukocytes, formaldehyde, oxidising agents, and azo dyes masking the pads. Optimum reading temperature 22–26 °C.

   Read it asThe manufacturer's multicentre data reports that 93% of samples negative for both leukocytes and nitrite were culture-negative, which is the basis for treating the strip as a rule-out rather than a rule-in test. The nitrite pad's two structural blind spots are the ones worth remembering: organisms that do not reduce nitrate (Enterococcus, Staph. saprophyticus, Pseudomonas) and insufficient bladder dwell time in someone voiding frequently because it hurts.

   Strong

Stroke

1. Calcium and vitamin D supplementation and fracture incidence

   Zhao J-G, Zeng X-T, Wang J, Liu L. JAMA 2017;318(24):2466–2482; with Bolland MJ, Reid IR and colleagues on the cardiovascular signal · 2017

   SupportsThe calcium section of the bone chapter: a meta-analysis of 33 randomised trials and 51,145 community-dwelling adults over 50 finding no significant association between calcium, vitamin D, or the combination and the incidence of hip fracture, vertebral fracture, non-vertebral fracture or total fracture.

   Read it asThe population matters and the chapter says so. This is community-dwelling older adults, and it does not overturn the older institutional trials in deficient, sun-deprived care-home populations where benefit was shown, nor does it apply to people who cannot meet the requirement from diet or who are starting a bone-protecting drug, which is generally given alongside calcium and vitamin D replacement. The cardiovascular signal reported by Bolland and Reid is contested — not reproduced in all analyses, mechanism debated — and the chapter presents it as a reason not to assume a supplement without fracture benefit is free, rather than as established harm.

   Strong

2. Mechanical loading and bone — spaceflight countermeasures and the LIFTMOR trial

   NASA International Space Station bone countermeasure programme, comparing the interim resistive exercise device with the Advanced Resistive Exercise Device (ARED); and Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR, LIFTMOR randomised controlled trial, Journal of Bone and Mineral Research 2018;33(2):211–220 · 2013–2018

   SupportsThat astronauts lose hip and spine bone at approximately 1–1.5% per month in microgravity despite controlled nutrition and calcium intake; that cardiovascular exercise and resistance loading limited to around 300 lb did not prevent that loss, while ARED at up to around 600 lb did. And LIFTMOR: post-menopausal women with a T-score below −1.0, randomised to 8 months of twice-weekly, 30-minute, supervised high-intensity resistance and impact training at above 85% of one-repetition maximum against a low-intensity home programme, with bone density improving at spine and hip in the training group against decline in controls — femoral neck +1.1% against −0.4% — alongside improved function and height, and good tolerability.

   Read it asThe supervision is load-bearing in the evidence, not a disclaimer. LIFTMOR participants were screened and every session was coached; the finding is that heavy loading is safe when taught and supervised in this population, which is a narrower claim than the one usually repeated from it. The spaceflight comparison is observational and uncontrolled in the formal sense, but the strength of the inference comes from the design of the setting rather than randomisation: same people, same controlled diet, same duration, with load magnitude as the variable that changed.

   Moderate

3. Osteonecrosis of the jaw — incidence at osteoporosis versus oncology doses

   Pooled estimates from post-marketing surveillance and cohort studies of oral nitrogen-containing bisphosphonates in osteoporosis; with the American Association of Oral and Maxillofacial Surgeons position papers and national cohort data on tooth extraction as a risk factor · current

   SupportsThe proportionality argument in the bone chapter: that osteonecrosis of the jaw with oral bisphosphonates at osteoporosis doses is commonly estimated at around 1 case per 100,000 patient-years, was not reported as an adverse event across tens of thousands of patient-years in the randomised osteoporosis trials, and is a different proposition from the condition described in oncology patients receiving intravenous bisphosphonates at roughly ten times the dose. That tooth extraction during treatment is the clearest risk factor, raising risk substantially, which is the basis for completing dental work before starting where practical.

   Read it asThis entry exists because the risk is routinely misrepresented in the direction that causes harm. Source material for this chapter described jaw osteonecrosis as “the major potential side effect” of bisphosphonates; at osteoporosis doses that overstates it by orders of magnitude, and the fracture being prevented is common — hip fracture carries roughly 20–30% one-year mortality with a large proportion of survivors losing independent living. Reported incidence varies considerably between cohorts, with some national datasets giving higher figures than 1 per 100,000, particularly with longer duration and after extraction; the chapter gives the commonly cited estimate and names extraction as the modifiable factor rather than presenting a single precise rate. Atypical femoral fracture is covered separately as the usual reason for a treatment break.

   Strong

4. Epicardial adipose tissue — semaglutide, SGLT2 inhibitors and the surrogate problem

   STOP trial prespecified analysis, Journal of the American College of Cardiology 2024 (semaglutide, n=115 with type 2 diabetes and known coronary disease); Khanna S et al., International Journal of Obesity 2026 (multimodality meta-analysis, 11 studies, 284 patients); and a systematic review and meta-analysis of randomised trials of SGLT2 inhibitors on adipose distribution, Diabetol Metab Syndr 2023 · 2023–2026

   SupportsThe epicardial fat section of the exercise and body composition chapter: that epicardial adipose tissue lies in direct contact with myocardium without an intervening fascial barrier and shares the coronary microcirculation; that semaglutide reduced epicardial fat volume by approximately 9% against placebo with a 5% increase in fat density over a year in the STOP imaging analysis; and that the SGLT2 evidence is inconsistent — a 2026 multimodality meta-analysis reporting a significant reduction (Hedges g −0.62) against a randomised-trial meta-analysis finding no significant effect on epicardial fat (SMD 0.03, 95% CI −0.52 to 0.58) while showing clear reductions in visceral, subcutaneous and hepatic fat.

   Read it asGraded Contested, and the reason is the same one the site applies to inflammation generally. The causal chain offered for epicardial fat — it secretes IL-6, IL-6 drives coronary disease, therefore reducing the fat prevents events — has a broken middle link: ZEUS suppressed IL-6 directly in over 6,300 people and produced a hazard ratio of 0.99. Epicardial fat volume is therefore a surrogate, and no trial has tested whether reducing it reduces events. The semaglutide finding is best read as a candidate mechanism for a cardiovascular benefit already established by outcome trials, not as a reason to take the drug. Source material for this section claimed SGLT2 inhibitors produce “the largest reductions in heart fat of anything studied”; the randomised evidence does not support that, and the chapter says so.

   Contested

5. NICE NG193 — chronic primary pain, and what it says about drugs

   NICE NG193, Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain, April 2021 · 2021

   SupportsThe fibromyalgia treatment chapter, which is anchored to it: fibromyalgia falls within chronic primary pain, and the guideline recommends a supervised exercise programme and psychological therapy — CBT or acceptance and commitment therapy — as core treatment rather than as adjuncts; offers antidepressants as an option, all off-label for this indication; and advises against starting opioids, NSAIDs, paracetamol, benzodiazepines, corticosteroids and antiepileptics including the gabapentinoids.

   Read it asThis corrected the chapter's gabapentinoid row, and the correction matters because UK and US practice genuinely diverge here. Pregabalin is licensed for fibromyalgia in the United States and trial evidence exists — but a UK GP following NG193 will not usually initiate it, so describing it as “reasonable to try” misdescribed the position a reader would actually meet. The page now separates starting from already taking: for someone established on one the guidance is to review whether it helps and discuss reducing or stopping if not, never to stop abruptly. The opioid row already matched the guideline, including the slow-taper language, and is unchanged. The shape of NG193 is itself worth noticing: a pain guideline whose central recommendations are not medicines.

   Strong

6. The genetic architecture of fibromyalgia across 2.5 million individuals

   Kerrebijn I, Bjornsdottir G, Arbabi K, et al. (Chronic Pain Genomics Consortium, FinnGen, DBDS Genomic Consortium, Estonian Biobank Research Team, Genes & Health Research Team). Nature Medicine, published online 28 July 2026, doi:10.1038/s41591-026-04492-6; PMID 41001472 · 2026

   SupportsThe fibromyalgia topic: a multi-ancestry GWAS meta-analysis across 2,563,755 individuals — 54,629 cases and 2,509,126 controls — from 11 cohorts, about 90% of European ancestry, identifying the first 26 risk loci for fibromyalgia. The strongest association was rs149109767-A, an in-frame glutamic acid deletion in exon 58 of the 67-exon HTT gene (odds ratio 1.09, p = 2.2 × 10⁻¹²) — part of the Huntington-disease-associated ‘A1’ haplotype in Europeans but far from the exon 1 repeat expansion that causes the disease. Gene prioritisation implicated the HTT regulator GPR52 plus CAMKV, DCC, DRD2/NCAM1, MDGA2 and CELF4. Heritability was exclusively enriched within brain tissues and neural cell types, peaking in hippocampal dentate gyrus and enteric neurons. Genetic correlation above 0.7 with chronic low back pain, post-traumatic stress disorder and irritable bowel syndrome.

   Read it asTwo things are commonly reported loosely and the topic corrects both. First, the HTT signal is not the Huntington mutation, does not raise anyone’s risk of Huntington’s disease, and confers about 9% higher odds — a population shift, not a diagnosis. Second, “not autoimmune” overstates it: the study found heritability enriched exclusively in neural tissue and positive genetic correlation with autoimmune as well as psychiatric and somatic conditions. Those are compatible — where the heritable risk sits is the brain; what it shares genetic ground with is broad. The authors’ own limitations are stated on the page: the cohort is predominantly European, limiting generalisability, and cases were ascertained from diagnostic codes, so people not meeting full syndromic criteria may be included and undiagnosed people are necessarily excluded — which, given the diagnostic history, is not a random exclusion. A GWAS establishes where the heritable signal lies, not mechanism, and the topic says so and states plainly that no treatment changes as a result.

   Strong

7. Lancet Commission on dementia prevention, intervention and care 2024

   Livingston G et al., Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission, The Lancet, published 31 July 2024 and presented at AAIC 2024 · 2024

   SupportsThe dementia chapter: 14 modifiable risk factors with an estimated 45% of dementia worldwide potentially preventable or delayed if all were eliminated. Two factors added in 2024: raised LDL cholesterol in midlife, at about 7% of cases, on evidence including a meta-analysis of three UK cohorts in which each 1 mmol/L higher LDL was associated with approximately 8% higher all-cause dementia incidence; and untreated vision loss in later life, at about 2%. Population attributable fractions recalculated using the Norwegian HUNT study. The two largest contributors globally are hearing impairment and raised LDL. And that addressing these factors matters even in people at high genetic risk.

   Read it asThe chapter spends its first section on what the 45% figure is not, because it is quoted everywhere as though it were a personal risk reduction. It is a population attributable fraction: it assumes causality, assumes complete elimination, and cannot have its components added together because the factors overlap heavily in the same people. Much of it — education, air pollution, deprivation — is structural rather than individual. What it does establish is direction and priority, which is genuinely new: dementia was widely presented as bad luck twenty years ago. The chapter is placed in the heart topic rather than longevity because the modifiable risk is largely vascular and every relevant factor already has a chapter there.

   Strong

8. Herpes zoster vaccination and dementia — the Wales natural experiment

   Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P. A natural experiment on the effect of herpes zoster vaccination on dementia, Nature 2025;641(8062):438–446, doi:10.1038/s41586-025-08800-x; with Xie M et al., Cell 2025;188(25):7049–7064, on effects at different stages of the disease course · 2025

   SupportsSection 5 of the dementia chapter: that Welsh zoster vaccination eligibility from 1 September 2013 was determined by exact date of birth, those born before 2 September 1933 being permanently ineligible; that vaccination uptake rose from about 0.01% among those one week too old to 47.2% among those one week younger; and that regression discontinuity analysis across that boundary found the live-attenuated vaccine reduced new dementia diagnoses over seven years by approximately one fifth. Negative-control analyses showed no effect on other causes of mortality or morbidity, and no increased uptake of other vaccinations or preventive measures.

   Read it asThe design is the point, and the chapter explains why. Ordinary vaccine research is defeated by the fact that people who get vaccinated are healthier and more engaged with healthcare than people who do not; a birth-date cutoff removes that entirely, and the negative controls behaving correctly is what a confounded result usually fails. Replicated in Australia by the same method, with concordant signals reported from England, New Zealand and Canada, and a separate US analysis of the Zostavax-to-Shingrix switch pointing the same way. Caveats stated on the page: not randomised; the effect appeared largely in women in both natural experiments and the reason is unknown; the mechanism is unsettled; and the product studied was the older live-attenuated vaccine rather than the recombinant one now in use. A randomised trial is being sought. The chapter draws a narrow practical conclusion — take up the vaccine you are offered rather than defer it — and explicitly does not present it as a dementia treatment.

   Moderate

9. NHS screening programmes in England — ages and intervals

   NHS.uk, NHS screening; NHS England public health commissioning pages; NHS England statements on the completed bowel screening age extension (2026) and the Targeted Lung Health Check programme · checked August 2026

   SupportsThe entitlement table in life health checks: cervical screening 25–64, five-yearly, HPV-first; NHS Health Check 40–74, five-yearly; bowel screening 50–74 by FIT every two years, the age extension from 60 down to 50 now complete, with kits available on request from 75 via 0800 707 6060; breast screening 50–70 every three years with self-referral thereafter; Targeted Lung Health Checks for ever-smokers aged 55–74 in parts of England; and a one-off abdominal aortic aneurysm ultrasound for men at 65.

   Read it asAges and intervals differ between the four UK nations and are revised periodically, and the topic says on every page that the invitation letter is the authority rather than the table. Three entitlements are given prominence because uptake data and common experience suggest they are widely unknown: the Health Check generally has to be booked rather than arriving unprompted, breast screening can be self-referred after 70, and bowel kits can be requested after 74. Overall bowel screening uptake was reported at 65.2% for 2024–25, and only about 56% among 54-year-olds — which is the specific gap the chapter is written against.

   Strong

10. MHRA June 2026 — strengthened ACE inhibitor angioedema warning

    MHRA Safety Roundup, June 2026, GOV.UK · June 2026

    SupportsThe angioedema row in the blood pressure chapter and the note on the treatment review page: that the product information for all ACE inhibitors is being updated to strengthen warnings about delayed-onset angioedema, which may occur after weeks to years of treatment; and that bradykinin-mediated angioedema does not respond to standard anaphylaxis treatment, so healthcare professionals should consider it when that treatment is ineffective.

    Read it asThis confirms rather than changes what the chapter already said — the delayed-onset point and the bradykinin-versus-histamine distinction were both already there — but a regulator formally strengthening a warning is worth date-stamping, and it sharpens one clinical point: failure to respond to standard anaphylaxis treatment is itself a diagnostic clue rather than a reason to give more. The site deliberately does not carry batch recalls, and the review page says so and explains why: recalls are lot-specific, handled through manufacturers and pharmacies, and any list would be stale within weeks while worrying more people than it helped. Regulatory changes that outlast a batch are carried; a recall ticker is not.

    Strong

11. TIME trial — morning versus evening dosing of antihypertensives

    Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study), The Lancet 2022;400(10361):1417–1425; with the MAPEC and Hygia Chronotherapy trials and the published critiques of them · 2022

    SupportsThe dosing-time section of the treatment review tool: a prospective, randomised, open-label, blinded-endpoint trial in 21,104 UK adults randomised to evening or morning dosing of their usual antihypertensives, finding no difference in the primary composite of vascular death or hospitalisation for non-fatal myocardial infarction or stroke over a median 5.2 years — hazard ratio 0.95 (95% CI 0.83–1.10) — and no difference in all-cause mortality.

    Read it asThis settles a question the internet has not caught up with. The MAPEC and Hygia Chronotherapy trials, both from a single Spanish group, reported very large reductions in cardiovascular events with bedtime dosing — Hygia an adjusted hazard ratio of 0.55 — and those effect sizes were widely judged implausible, with a 2022 systematic review finding all eight relevant studies at high risk of bias. TIME is the independent, large, pragmatic test and it is null. The practical conclusion the page draws is about adherence rather than chronobiology: take them when you will actually remember, which for most people is the morning. The one stated exception is documented high night-time blood pressure on ambulatory monitoring, where evening dosing may still be considered — and the page is explicit that this is a specific finding rather than something to infer from home readings.

    Strong

12. Inter-arm blood pressure difference and the ankle-brachial index

    Clark CE, Warren FC, Boddy K, et al., Associations between systolic interarm differences in blood pressure and cardiovascular disease outcomes and mortality: individual participant data meta-analysis — the INTERPRESS-IPD collaboration, Hypertension 2021;77:650–661; NICE NG136 and ESC hypertension guidance on measuring both arms; standard ankle-brachial index thresholds as used in vascular practice · 2021 and current

    SupportsThe blood pressure measurement page and calculator: that a systolic inter-arm difference of 10 mmHg or more is generally taken as the upper limit of normal and is present in about 3.6% of the general adult population, 7.4% of people with diabetes and 11.2% of people with hypertension; that in pooled individual participant data from more than 50,000 people across 24 cohorts with 10 years of follow-up a difference at that level was associated with higher cardiovascular events, cardiovascular mortality and all-cause mortality independent of standard risk scores; and that NICE and the ESC treat 15 mmHg as the threshold of additional cardiovascular risk. Also the ABI bands: above 1.40 non-compressible, 1.00–1.40 normal, 0.91–0.99 borderline, 0.90 or below indicating peripheral arterial disease, below 0.40 severe.

    Read it asTwo points the calculator is built around because they are routinely missed. First, an ABI above 1.40 is not a good result — it usually means the ankle arteries are too calcified to compress, renders the test uninterpretable and carries raised risk of its own; treating a high number as reassuring is the commonest misreading of the test. Second, an automatic upper-arm monitor is not validated at the ankle, so a home ABI is a prompt to ask rather than a result, and specifically not an all-clear. The tool also requires symptoms as well as numbers before raising acute aortic dissection, because a large inter-arm difference alone is common and the alternative would generate alarm in people who mostly have measurement variation. Sequential rather than simultaneous measurement exaggerates inter-arm differences, which is why the page insists on confirmation before acting.

    Strong

13. Approved elsewhere, not available in the UK — three 2025–26 notices

    Tonmya: Tonix Pharmaceuticals and FDA approval announcements, 15 August 2025; RELIEF and RESILIENT Phase 3 trials, the latter published in Pain Medicine. Baxfendy: AstraZeneca and FDA announcements, 18 May 2026; BaxHTN, New England Journal of Medicine 2025, NCT06034743; Bax24, The Lancet March 2026. Foundayo: Eli Lilly and FDA announcements, 1 April 2026; ATTAIN-1 (NCT05869903) and ATTAIN-2 · checked 15 August 2026

    SupportsThree “what exists elsewhere” notices. Tonmya (cyclobenzaprine HCl sublingual 5.6 mg) in the fibromyalgia treatment chapter: FDA-approved 15 August 2025, once nightly, targeting non-restorative sleep, the first new fibromyalgia approval in over fifteen years and the fourth ever after pregabalin (2007), duloxetine (2008) and milnacipran (2009); two positive Phase 3 trials in about 1,000 people (RELIEF, NCT04172831; RESILIENT, NCT05273749), both significant on daily pain at 14 weeks — and a third, RALLY (NCT04508621), which randomised 514 people and failed its primary endpoint, stopped early on interim analysis in July 2021. Dosing is 2.8 mg tablets, one nightly for two weeks then two (5.6 mg), with a 2.8 mg maximum in older adults and mild hepatic impairment. Baxfendy (baxdrostat) in the blood pressure chapter: FDA-approved 18 May 2026, first-in-class oral aldosterone synthase inhibitor; BaxHTN randomised 796 patients on standard care, placebo-adjusted seated systolic reduction at 12 weeks of 9.8 mmHg (2 mg) and 8.7 mmHg (1 mg), with about 14 mmHg on 24-hour ambulatory monitoring in resistant hypertension. Foundayo (orforglipron) in the exercise and body composition chapter: FDA-approved 1 April 2026, first small-molecule oral GLP-1 for chronic weight management, no food or water restriction; ATTAIN-1 randomised 3,127 adults without diabetes, losing 7.5–11.2% of body weight at 72 weeks against 2.1% on placebo.

    Read it asAll three are reported under the rule set out in the ezetimibe chapter — a genuine advance gets reported with its status attached — and all three are date-stamped, because each will move. Each carries a deflation that the promotional coverage does not. Tonmya is a reformulation of a 1977 muscle relaxant rather than a new molecule, its effect sizes sit in the same range as the existing options, and “first-line treatment” is the manufacturer’s phrase, attributed and not adopted, since NG193 is unchanged; the null trial is named, per the practice established for JELIS, because a drug’s evidence base is the trials that were run rather than the trials that read well; cyclobenzaprine has never been UK-marketed in any form, and neither was milnacipran, so American and British options for this condition have differed for fifteen years rather than one. Baxdrostat is approved on blood pressure, a surrogate, with no outcome trial, hyperkalaemia in up to about one in ten at the higher dose, and no head-to-head against spironolactone — so the page states that spironolactone remains the UK step-4 answer. Orforglipron is framed as an access advance rather than an efficacy one: BaxHTN excluded people already taking a mineralocorticoid receptor antagonist or potassium-sparing diuretic, which is why it cannot speak to how baxdrostat compares with or adds to spironolactone. And orforglipron’s weight loss sits below semaglutide and tirzepatide, both already UK-available, on a cross-trial comparison labelled as such, and the manufacturer concedes the gap.

    Strong

14. Tick bites, Lyme disease and tick-borne encephalitis in the UK

    NICE NG95, Lyme disease: diagnosis and management (2018, with rationale and impact documents); UKHSA, Defra and APHA joint report on vector-borne disease, May 2026; Holding M et al. and colleagues, Tick-borne encephalitis: from tick surveillance to the first confirmed human cases, the United Kingdom, 2015 to 2023, Eurosurveillance 2025; UKHSA report of a probable UK-acquired TBE case, July 2019; IDSA/AAN/ACR Lyme disease guideline 2020; CDC, What to Do After a Tick Bite, reviewed 9 June 2026; Bryant KA, When Does a Tick Bite Need Antibiotics?, Medscape commentary, May 2026 · 2018–2026, checked August 2026

    SupportsThe tick chapter. From NG95: erythema migrans as a clinical diagnosis treated on sight without testing; doxycycline 100 mg twice daily for 21 days for adults and young people 12 and over, amoxicillin 1 g three times daily for 21 days as the alternative and in pregnancy, doxycycline 200 mg twice daily or intravenous ceftriaxone where the central nervous system is involved, and no azithromycin in cardiac involvement because of QT effects; specialist discussion for anyone under 18 except a child of 9 to 12 with a single erythema migrans and no other features; two-tier serology with ELISA then immunoblot and repeat testing at 4 to 6 weeks if negative with persisting symptoms. From the May 2026 UKHSA and Defra report: 1,168 laboratory-confirmed Lyme cases in England in the reporting year, up from 959 and comparable to 1,151 in 2023, and six UK-acquired tick-borne encephalitis cases in total with the virus limited to Thetford Forest, the New Forest, Dartmoor and Devon, North Yorkshire and parts of Scotland.

    Read it asThe chapter names the UK/US divergence in both directions rather than picking a side. The IDSA recommends a single 200 mg dose of doxycycline within 72 hours, but only where all its high-risk criteria are met — an Ixodes tick, a highly endemic area, and attachment for 36 hours or more — and states that monitoring is otherwise as effective; most UK bites do not meet that bar. It also flags that the UK treats erythema migrans for 21 days and the US for 10, and says plainly that both are defensible readings of thin evidence, so a reader comparing sources does not conclude one is wrong. Section 7 on persistent symptoms is written to hold two things together: prolonged antibiotics have been tested in randomised trials, do not help and do cause harm — and that is not the same as saying the symptoms are imagined. It warns specifically about non-validated private testing, and points at the treatable alternatives a Lyme label can close off. The TBE figures will date and are marked as a May 2026 position; louping ill virus cross-reactivity is noted as a diagnostic complication rather than a disease risk. Round 100 corrected one error and closed three gaps after reading the CDC page and the Medscape commentary in full. The removal list had said not to use fingers; that was stricter than CDC guidance and would cause the delay the guidance exists to prevent, so the section now leads with do not wait to see anyone and permits ordinary tweezers or fingers over waiting. The tick-testing argument went from one reason to four — commercial labs not held to clinical diagnostic standards, a positive not meaning infection, a negative being falsely reassuring because another tick may have been missed, and results arriving after symptoms would. And a travel section was added, because the American lone star tick causes illnesses absent from the UK: ehrlichiosis with a rash in up to 60% of infected children, tularemia, Bourbon and Heartland viruses, alpha-gal syndrome, and STARI — an expanding rash that mimics erythema migrans and is not Lyme disease. Rocky Mountain spotted fever is named as treated urgently on suspicion with no role for prophylaxis, and the European TBE belt as a travel-vaccine conversation rather than an afterthought.

    Strong

15. PCSK9 — genetics, outcome trials and UK eligibility

    Abifadel M et al., Nature Genetics 2003;34:154–156; Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH, New England Journal of Medicine 2006;354:1264–1272; Sabatine MS et al. (FOURIER), NEJM 2017;376:1713–1722; Giugliano RP et al. (EBBINGHAUS), NEJM 2017;377:633–643; Schwartz GG et al. (ODYSSEY OUTCOMES), NEJM 2018;379:2097–2107; Ridker PM et al. (SPIRE, bococizumab), NEJM 2017;376:1527–1539; Ference BA et al., NEJM 2016;375:2144–2153; O’Donoghue ML et al. (FOURIER-OLE), Circulation 2022;146:1109–1119; Navar AM et al., NEJM 2026;394:529–539; NICE TA393, TA394, TA733 · 2003–2026, criteria checked August 2026

    SupportsThe PCSK9 chapter: the loss-of-function genetics — roughly 1 in 40 Black participants in the Cohen cohort carrying a nonsense variant, with LDL about 28% lower and coronary heart disease 88% lower, and a milder variant in white participants giving about 15% lower LDL and 47% lower risk; FOURIER, 27,564 patients, LDL 2.4 to about 0.8 mmol/L and major events down 15% (HR 0.85) over a median 2.2 years; ODYSSEY OUTCOMES, 18,924 patients, events down 15%; EBBINGHAUS finding no cognitive difference including at very low LDL; the bococizumab failure through anti-drug antibodies; and the eligibility thresholds — antibodies above 4.0 mmol/L at high risk or 3.5 at very high risk (recurrent events or more than one vascular bed), 5.0 for heterozygous FH without cardiovascular disease, against inclisiran’s 2.6 with prior events and primary care initiation.

    Read it asThis page was drafted by the reviewing AI and integrated rather than written here, and it is not yet clinically signed. Several figures the drafter flagged as unverified have been hedged rather than stated precisely — lerodalcibep’s percentage, the Lp(a) reduction range, and the plaque-imaging trial figures — and list prices were dropped entirely rather than guessed. Two internal links were corrected during integration: the gene-editing cross-reference points at section 8 of the ezetimibe chapter, where that content lives, not at the genetics page. The ezetimibe ladder was shortened to point here rather than repeat the eligibility detail, so the two pages cannot drift.

    Strong

16. PCSK9 inhibition in the UK — who may prescribe, and what exists elsewhere

    NICE TA393 (alirocumab), TA394 (evolocumab), TA733 (inclisiran); NHS England lipid management and inclisiran access guidance; ICB primary care prescribing guidance for inclisiran; Navar AM et al., New England Journal of Medicine 2026;394:529–539; FDA press announcement and Merck release on the approval of Lipfendra (enlicitide), 16 July 2026; NICE appraisal in progress for obicetrapib (ID6519, final scope January 2026, publication expected 14 October 2026) · checked August 2026

    SupportsThe step-4 row of the ladder in the ezetimibe chapter and the pathway line in the clinical depth: that the PCSK9 monoclonal antibodies alirocumab and evolocumab are specialist-initiated only, while inclisiran was appraised and is commissioned for initiation in primary care — for adults with a history of cardiovascular events whose LDL-C remains at or above 2.6 mmol/L on maximally tolerated statins — given twice yearly after loading doses. And section 7: that enlicitide (Lipfendra), a once-daily 20 mg oral macrocyclic peptide, was approved by the FDA on 16 July 2026, lowering LDL-C by a placebo-adjusted 56% and 59% at 24 weeks in its two registration trials, with no UK licence and no NICE appraisal as at 15 August 2026, and its cardiovascular outcome trial CORALreef Outcomes unreported.

    Read it asThis corrected a real error on the site. The clinical page previously described everything beyond bempedoic acid as specialist-led, which is right for the antibodies and wrong for inclisiran — the one agent in the class a GP can and is expected to start. That distinction is poorly known and is a plausible contributor to underuse, so the chapter now states it explicitly rather than leaving the class described as a single thing — with a visible dated correction note on the page, per the practice established for the VitaK-CAC error, because the old wording had a practical consequence rather than being merely imprecise. For scale, Greater Manchester reported roughly 1,900 people receiving inclisiran against an estimated 3,700 eligible. The correction was applied across three pages — the ladder, the clinical referral criterion and the calculator drug card — after the first pass fixed only one of them, which is the same cross-page failure mode as the round-36 choking correction. On enlicitide, the editorial rule is stated on the page: a genuine advance is reported with its status attached, because a UK reference that described only UK availability would leave a clinician unable to answer what a well-read patient asks. And the surrogate discipline is applied unchanged — enlicitide is approved on LDL reduction with its cardiovascular outcome trial unreported, which is the same position as inclisiran; a second example in the class does not strengthen the surrogate, it clarifies the pattern.

    Strong

17. NICE NG136 — antihypertensive choice, monitoring and adverse effects

    NICE NG136, Hypertension in adults: diagnosis and management, visual summary updated July 2025; NHS Specialist Pharmacy Service guidance on ACE inhibitor and ARB monitoring and on calcium channel blocker peripheral oedema; MHRA drug safety updates on ACE inhibitors and ARBs in pregnancy (2007) and breastfeeding (2009) · 2019, updated 2025

    SupportsSection 7 of the blood pressure chapter: the A/C/D sequence — ACE inhibitor or ARB at step 1 for adults under 55 not of Black African or African-Caribbean family origin and for type 2 diabetes at any age, calcium channel blocker for those 55 or over or of Black African or African-Caribbean family origin, thiazide-like diuretic where a CCB is not tolerated because of oedema; A+C or A+D at step 2; A+C+D at step 3; and spironolactone at step 4 where potassium is 4.5 mmol/L or below, otherwise an alpha or beta blocker. That beta blockers are not recommended as routine initial therapy for hypertension. That an ARB is preferred to an ACE inhibitor in adults of African and Caribbean family origin, the committee’s stated reason being an increased risk of angioedema. That an ACE inhibitor and an ARB are not combined. That NICE names cough as a reason to switch from an ACE inhibitor to an ARB, and oedema as a reason to switch from a CCB to a thiazide-like diuretic. And that kidney function and potassium are checked within 1–2 weeks of starting or increasing an ACE inhibitor or ARB, then periodically.

    Read it asTwo things in that section are framed more strongly than the source documents phrase them, deliberately. The triple whammy — ACE inhibitor or ARB plus diuretic plus NSAID — is a well-recognised cause of acute kidney injury in primary care and is presented here as something a patient should actively ask about, because the NSAID is frequently bought over the counter and never mentioned. And sick day rules are described as usual practice with an explicit instruction to confirm the plan with the person’s own prescriber, because local guidance varies and the page should not be the authority for holding a prescribed drug. The incidence figures — ACE inhibitor cough at roughly 1 in 10 with a range of 1 in 20 to 1 in 3, amlodipine oedema rising from about 1 in 50 at 2.5 mg to about 1 in 10 at 10 mg and roughly threefold over placebo, orthostatic hypotension in about one in five over-60s and around half of care home residents — are drawn from the meta-analytic and review literature cited in the further reading rather than from NG136 itself.

    Strong

18. NICE NG246 — waist-to-height ratio and central adiposity

    National Institute for Health and Care Excellence, NG246, Overweight and obesity management (2025), consolidating and replacing CG189; recommendations dated 2022 · 2022 recommendations, republished in NG246 2025

    SupportsThe waist-to-height bands in the exercise and body composition chapter: 0.40–0.49 healthy central adiposity, 0.50–0.59 increased, 0.60 or above high, applicable to both sexes and all ethnicities including adults with high muscle mass, and to be measured in adults with a BMI below 35 alongside BMI. That NICE asks clinicians to explain it as keeping the waist to less than half the height. And that the guidance asks for permission before discussing overweight, obesity or central adiposity and before taking measurements, with a refusal respected without judgement.

    Read it asWhy the ratio beats the circumference tables above it on the same page. Raw waist circumference needs separate thresholds by sex and by ethnicity; the 0.5 cut-off has held across both in the underlying evidence, which is why NICE applies one number to everyone. It is also the measure that catches central adiposity at a BMI in the healthy range, which is where BMI fails hardest. Above BMI 35 it stops discriminating, because nearly everyone in that group exceeds it — hence the restriction. NICE separately advises lower BMI thresholds for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background.

    Strong

19. In vivo base editing of PCSK9 with VERVE-102 — the Heart-2 trial

    Vafai SB, Täubel J, Ashdown T, et al. New England Journal of Medicine 2026, published online 25 May 2026; presented at the European Atherosclerosis Society Congress. ClinicalTrials.gov NCT06164730. Funded by Verve Therapeutics, a wholly owned subsidiary of Eli Lilly · 2026

    SupportsSection 7 of the ezetimibe chapter: that VERVE-102 is an adenine base editor plus guide RNA delivered in a GalNAc lipid nanoparticle as a single intravenous infusion of about four hours, permanently inactivating PCSK9 in hepatocytes. Interim Phase 1b analysis of 35 participants with heterozygous familial hypercholesterolaemia or premature coronary artery disease: dose-dependent mean PCSK9 reductions of 51% to 88%, LDL cholesterol reduced by up to 62% at the highest dose — an absolute fall of about 78 mg/dL — with durability reported as at least one year in 15 participants. Around 20% had grade 1 or 2 infusion-related reactions; one serious adverse event occurred. FDA Fast Track designation granted.

    Read it asPhase 1b, 35 people, no cardiovascular outcome data, and none for years. The chapter grades it Emerging and states explicitly that nothing here has prevented a single heart attack. Two points the chapter makes that the trial reports do not emphasise: this is somatic editing of liver cells and is not heritable, which is the confusion that makes the technology sound more alarming than it is; and permanence is the whole question in both directions — it removes the adherence problem that defeats about half of lipid prescriptions within a year, and it removes the ability to stop if a late signal appears. The predecessor VERVE-101 encountered liver enzyme and platelet signals; the delivery particle was redesigned for VERVE-102, which has so far avoided them. The LDL endpoint is a surrogate, but an unusually well-validated one — lowering LDL has cardiovascular outcome evidence across four pharmacologically distinct mechanisms — statins (HMG-CoA reductase), ezetimibe (NPC1L1), PCSK9 monoclonal antibodies, and bempedoic acid (ATP-citrate lyase, CLEAR Outcomes) — with Mendelian randomisation pointing the same way across the corresponding genes. That is why the chapter treats it differently from the epicardial fat and IL-6 surrogates elsewhere on the site. Inclisiran is deliberately excluded and named on the page as the counter-example: it lowers LDL substantially through the same PCSK9 pathway as the antibodies, so it is not even a distinct mechanism, and its outcome trials — ORION-4 and VICTORION-2 Prevent — have not reported. It is a drug licensed on the strength of the surrogate rather than evidence for it.

    Emerging

20. Ezetimibe — NPC1L1 genetics, IMPROVE-IT, and the ENHANCE surrogate failure

    Myocardial Infarction Genetics Consortium Investigators, NEJM 2014;371:2072–2082 (NPC1L1 inactivating mutations); Cannon CP et al., IMPROVE-IT, NEJM 2015;372:2387–2397; Kastelein JJP et al., ENHANCE, NEJM 2008;358:1431–1443; Garcia-Calvo M et al., PNAS 2005;102:8132–8137 (target identification) · 2005–2015

    SupportsThe ezetimibe chapter: that ezetimibe inhibits NPC1L1 in the intestine, blocking uptake of both dietary and biliary cholesterol, and that the target was identified in 2005, three years after approval. That carriers of naturally inactivating NPC1L1 mutations have LDL lower by about 12 mg/dL (0.3 mmol/L) from birth and about 53% less coronary heart disease. That IMPROVE-IT randomised 18,144 patients after acute coronary syndrome and found a 7-year event rate of 32.7% against 34.7% (absolute difference 2.0 points, hazard ratio 0.936, 95% CI 0.89–0.99, p = 0.016), with time-weighted average LDL of 53.7 against 69.5 mg/dL, and no difference in all-cause mortality (15.3% vs 15.4%) or cardiovascular death (6.8% vs 6.9%), and no excess of muscle, gallbladder, hepatic events or cancer. And that ENHANCE, in familial hypercholesterolaemia, found no difference in carotid intima-media thickness despite a larger LDL reduction.

    Read it asIMPROVE-IT is frequently described as having “definitively proven” ezetimibe. It did not. A 2-point absolute difference over seven years is a number needed to treat of about 50, with no mortality signal in either direction, and the chapter says so. Its real importance is what it established about LDL rather than about the drug: lowering LDL further by a non-statin mechanism produced approximately the benefit the LDL difference predicted, which is strong evidence that the LDL reduction is doing the work. ENHANCE is the site’s clearest worked example of a surrogate failure — carotid wall thickness, measured over two years in long-treated FH patients whose arteries were already thickened, was close to the least sensitive endpoint available.

    Strong

21. Ez-PAVE — intensive versus conventional LDL targeting in established ASCVD

    Kim B-K et al., Yonsei University College of Medicine, presented at ACC 2026 and published in the New England Journal of Medicine; NCT04626973 · 2026

    SupportsThe target comparison in the ezetimibe chapter: 3,048 patients with established atherosclerotic disease at 17 South Korean sites, randomised to an LDL target below 55 mg/dL or below 70 mg/dL, with therapy at physician discretion. At 3 years the primary composite — cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, any revascularisation or hospitalisation for unstable angina — occurred in 6.6% against 9.7% (hazard ratio 0.67, 95% CI 0.52–0.86, p = 0.002; number needed to treat 32). Achieved median LDL 56 against 66 mg/dL. Safety was similar between groups.

    Read it asThree limits, all on the page. The trial was open-label, necessarily, because clinicians had to know the target — though outcomes were adjudicated blind. The benefit was driven mainly by revascularisation (4.8% against 7.5%), which is the softest component of the composite and the one most exposed to open-label design; the harder composite of cardiovascular death, myocardial infarction or stroke moved in the same direction (2.3% against 3.6%) on smaller numbers. And it was conducted entirely in an East Asian population, without access to inclisiran or bempedoic acid. Published commentary has argued on the revascularisation point that Ez-PAVE does not validate the <55 target, and the chapter reports that dissent rather than resolving it. Note also that the achieved LDL values differed by less than the target labels imply — 1.45 against 1.7 mmol/L.

    Moderate

22. VitaK-CAC — menaquinone-7 and coronary artery calcification

    Vossen LM, de Leeuw PW, Schurgers LJ, Heuts S, Adriaans BP, de Haan C, van Varik BJ, Kroon AA, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology, published online 10 June 2026; doi:10.1001/jamacardio.2026.1279. Protocol: Nutrients 2015;7(11):8905–8915 · 2026

    SupportsThe K2 section of the CAC chapter: a double-blind, placebo-controlled trial at two Dutch hospitals randomising 180 symptomatic patients (90 per group) with a baseline CAC of 50–400 Agatston units to 360 µg MK-7 daily or placebo for two years. 150 completed, 75 per arm. Median CAC rose from 145 to 214 AU on placebo and 135 to 184 AU on MK-7 (p = 0.02, holding after adjustment for covariates) — approximately 29% less progression by Agatston score and 42% less by calcium mass. Median age 59–61, 42% women, 78% on statins, no high-risk plaque at baseline, 80% adherence and a 17% dropout rate, which reconciles with 180 rather than 167. Secondary finding: the rise in CAC score correlated with the number of non-calcified plaques becoming partially calcified (p = 0.04). Stenosis severity progressed in about 33% of the MK-7 arm and 41% of placebo, with no significant between-group difference — a null comparison rather than an absence of progression. Plasma MK-7 rose from 0.50 to 6.56 µg/L, confirming the intervention was taken.

    Read it asNote on the participant count: the ACC journal scan reports “167 randomised”, which does not reconcile with a 17% dropout and 150 completing; 180 randomised does. The figures asserted on the page are therefore 180 randomised and 150 completing only. A treated-population split has been seen in secondary coverage but is not quotable from a source checked here, so it is deliberately not stated. This entry also corrected an error on this site. An earlier version of the CAC chapter stated there was no trial showing K2 slows calcification progression on repeat scanning; VitaK-CAC is that trial, and the page now says so and says it was wrong. What has not changed is the more important claim: the endpoint is a surrogate, the trial was neither designed nor powered for cardiovascular events, and the authors state directly that whether slower calcification means fewer events is unanswered. Three further limits are on the page: recruitment ran from 2012 to 2022 with interruptions in a trial of 180 people; the population had symptomatic disease, was 78% statin-treated and had no high-risk plaque at entry; and the trial used a branded MK-7 preparation with the developing group inside the same university, which is the norm for supplement trials and worth seeing — the preparation was MenaQ7, originally Nattopharma, now part of Gnosis by Lesaffre. The dose gap is practically important: 360 µg was studied, 100–200 µg is typical on the shelf.

    Moderate

23. Spotty versus dense coronary calcification and plaque vulnerability

    Nakahara T et al., Coronary Artery Calcification: From Mechanism to Molecular Imaging, JACC: Cardiovascular Imaging; with the intravascular imaging literature on microcalcification and plaque rupture · current

    SupportsThat coronary calcium is not uniform: spotty or micro-calcification occurs within young, inflamed, lipid-rich plaque and is associated with greater inflammation and higher rupture risk, while dense or macro-calcification occurs in older plaque and is associated with lower inflammation and greater stability. And that a CT calcium score measures total calcium and cannot distinguish the two.

    Read it asThe chapter is careful to label the downstream inference as an inference. The observation that a calcium score can rise after lifestyle improvement or statin initiation is real; the explanation usually offered — that soft plaque is calcifying and stabilising as inflammation falls — is extrapolated from this literature rather than demonstrated by a trial, and the page says so rather than presenting it as established. The practical conclusion holds either way: a rising score alone is not evidence of deterioration, and a falling score is not a treatment target.

    Moderate

24. Coronary artery calcium, PREVENT risk and statin eligibility — MESA

    Rikhi R et al., Wake Forest University School of Medicine. Journal of the American College of Cardiology 2026; doi:10.1016/j.jacc.2026.05.039, published online 15 July 2026 · 2026

    SupportsThe MESA subsection in the CAC chapter: 5,698 adults without clinical ASCVD, mean age 61.5, 52.8% women, followed 10 years. Event rates per 1,000 person-years by 2026 ACC/AHA statin-eligibility band, CAC = 0 against CAC > 0 — not recommended 1.2 against 4.5; considered 2.7 against 5.2; recommended 5.8 against 16.6. In participants with LDL 70–189 mg/dL and no diabetes, CAC > 0 was associated with approximately twofold or higher event rates across all PREVENT risk tiers. Categorical net reclassification improvement 0.124, driven by appropriate reclassification of both events and non-events.

    Read it asFour limits, and the chapter states all of them. The design is observational, so it shows that CAC sorts people by risk rather than that acting on it improves outcomes. CAC results were not blinded to clinicians or participants, which biases toward the test looking useful. Risk was calculated with PREVENT against 2026 ACC/AHA thresholds — UK practice uses QRISK and NICE does not recommend calcium scoring for routine risk assessment, so the reclassification figure does not transfer, though the direction does. And the authors note MESA was a relatively healthy primary-prevention cohort, which will have lowered absolute event rates. An NRI of 0.124 is a measurable rather than dramatic gain, on a metric that is itself contested. The most useful single figure is the “not recommended” row, because it locates the benefit of scanning in the group a calculator has already dismissed.

    Moderate

25. Time to treatment with intravenous alteplase and outcome in stroke — pooled analysis

    Lees KR, Bluhmki E, von Kummer R, et al. Lancet 2010;375:1695–1703; with Emberson J, Lees KR, Lyden P, et al. individual patient data meta-analysis, Lancet 2014;384:1929–1935 · 2010 and 2014

    SupportsThe time-benefit table in the stroke chapter. Adjusted odds of a favourable 3-month outcome, modified Rankin 0–1: 2.55 (1.44–4.52) for 0–90 minutes, 1.64 (1.12–2.40) for 91–180, 1.34 (1.06–1.68) for 181–270, and 1.22 (0.92–1.61) for 271–360, the last no longer significant. Mortality odds rising with delay: 0.78, 1.13, 1.22, 1.49 across the same intervals. Number needed to treat about 14 in the 3-to-4.5-hour window.

    Read it asThe finding that makes the urgency argument, and it is easy to miss. Large parenchymal haemorrhage occurred in 5.2% of treated patients against 1.0% of controls with no relationship to how quickly treatment started. The benefit shrinks steeply with delay; the bleeding risk does not move. So the deteriorating balance is entirely a matter of giving up upside rather than accruing harm — which is why the chapter presents the two together.

    Strong

26. Tenecteplase against alteplase, and why the practical choice differs from the trial result

    AcT randomised trial (Canada); ATTEST-2, Lancet Neurology 2024; RAISE (reteplase); with the tenecteplase individual patient data meta-analysis, Int J Stroke 2016 · 2016–2024

    SupportsThat the two are equivalent on outcome — AcT: 36.7% against 35.9% free of significant disability at 90 days, odds ratio 1.03 (0.81–1.31), symptomatic haemorrhage 3.2% against 3.1%; ATTEST-2 confirming non-inferiority without superiority; reteplase also no different. And that tenecteplase is given as a single bolus of 0.25 mg/kg to a maximum of 25 mg, against a bolus plus one-hour infusion for alteplase.

    Read it asThe chapter argues for tenecteplase on logistics rather than on efficacy, and says so. Given that the odds of a good outcome fall from 2.55 to 1.34 across the treatment window, removing an infusion pump from the pathway — and with it the delay in starting and the difficulty of transferring a patient mid-infusion to a thrombectomy centre — converts into outcome even though the head-to-head trials show no difference. It is an unusual and instructive case: two equivalent drugs, one clearly better in a hospital.

    Strong

27. Thrombolysis beyond 4.5 hours — three trials, three answers

    TIMELESS, New England Journal of Medicine 2024 (NCT03785678); TRACE-III, New England Journal of Medicine 2024;391:203–212; HOPE, JAMA 2025;334(9); with a 2025 meta-analysis in Stroke · 2024–2025

    SupportsThe extended-window section of the stroke chapter. TIMELESS: tenecteplase 4.5–24 h in mostly thrombectomy-treated patients, no better than placebo; symptomatic intracranial haemorrhage 3.2% against 2.3%, mortality 19.7% against 18.2%. TRACE-III: tenecteplase 4.5–24 h in large-vessel occlusion without access to thrombectomy, 33.0% free of disability at 90 days against 24.2% (relative rate 1.37, 95% CI 1.04–1.81), symptomatic haemorrhage 3.0% against 0.8%, mortality unchanged at about 13%. HOPE: alteplase, more haemorrhage at 3.8% against 0.5%, no mortality difference.

    Read it asGraded Contested because the trials disagree, and the chapter presents them rather than a conclusion. On the TRACE-III figures the absolute benefit is about 8.8 percentage points, giving roughly 11 needing treatment for one extra disability-free outcome, against roughly 45 for one extra symptomatic bleed. That is a favourable trade for someone facing severe disability and it is a real trade. It applies only to the population studied: large-vessel occlusion, salvageable tissue on perfusion imaging, and no thrombectomy available. Within 4.5 hours the evidence remains Strong. Around 60% of patients arrive more than eight hours from onset, which is why the question matters so much.

    Contested

28. Standard-window thrombolysis, thrombectomy, and secondary prevention

    Pooled analyses of alteplase trials; thrombectomy trials with imaging selection to 24 hours; and UK secondary-prevention practice following NICE guidance · current

    SupportsThrombolysis within 4.5 hours of last known well with benefit falling steeply inside the window; symptomatic intracranial haemorrhage of a few per cent against about 1% untreated, with more early deaths but no difference in mortality at three to six months. Thrombectomy for large-vessel occlusion to 6 hours, extending to 24 in selected patients. Antiplatelet then clopidogrel, with a short dual course after minor stroke or high-risk TIA; anticoagulation replacing antiplatelet where atrial fibrillation is found; high-intensity statin; blood pressure; carotid surgery for symptomatic severe stenosis, most effective within two weeks.

    Read it asThe chapter states that a single ECG finds only a minority of paroxysmal atrial fibrillation and that prolonged monitoring finds substantially more — which matters because the finding changes treatment from an antiplatelet to an anticoagulant. It is the most consequential omission in an otherwise complete workup.

    Strong

Fainting

1. Collapse around exercise — postural collapse, heat illness and exercise-associated hyponatraemia

   Sports and exercise medicine consensus positions on exercise-associated collapse; heat illness guidance; and the exercise-associated hyponatraemia consensus statements · current

   SupportsThe exercise section of the fainting chapter: that collapse after stopping endurance effort is usually exercise-associated postural collapse, caused by loss of the leg muscle pump while vessels remain dilated, and resolves with recumbency and elevation of the legs and pelvis; that collapse during effort is treated as cardiac; that mental state rather than temperature separates heat exhaustion from heat stroke; and that exercise-associated hyponatraemia should be suspected where large volumes of plain water have been drunk with no weight loss or with weight gain, in which case further hypotonic fluid is harmful.

   Read it asThe during-versus-after distinction is the load-bearing one and is the reason the section exists. The hyponatraemia scenario is uncommon but is the one case in this chapter where the instinctive treatment — give them water — makes the patient worse, which is why it is named despite its rarity. Auditory prodromal symptoms, including muffling and popping, are a recognised part of presyncope and are described by patients far more often than they appear in warning-sign lists.

   Moderate

2. Syncope — assessment, red flags and physical counter-pressure

   ESC syncope guidelines and the NICE transient loss of consciousness guidance; with the Physical Counterpressure Manoeuvres Trial (PC-Trial) for the manoeuvres · current

   SupportsThe structure of the fainting chapter: the three high-risk features — syncope during exertion, syncope while supine, and syncope with no prodrome — as the features that reclassify a faint as a cardiac event; orthostatic hypotension defined as a fall of 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing; the value of an ECG in unexplained syncope; and that leg crossing, handgrip and arm tensing raise blood pressure enough to abort a reflex faint if begun during the prodrome.

   Read it asThe chapter states that a normal pulse afterwards excludes nothing, because the arrhythmia responsible has usually terminated by the time anyone reaches the wrist — which is the argument for an ECG rather than a pulse check. The 30-minute observation period is offered as a working default and labelled as such; no guideline specifies a bystander observation time.

   Strong

Emergency and first aid guidance

Everything in the emergency topic traces to one of these. Where they have been superseded, the superseding version is what the pages use.

1. Post-cardiac arrest care — 2025 AHA and ERC-ESICM guidelines

   Hirsch KG et al., Part 11: Post–Cardiac Arrest Care, 2025 AHA Guidelines, Circulation 2025; Nolan JP, Sandroni C et al., ERC-ESICM Guidelines 2025: Post-resuscitation care, Intensive Care Medicine 2025; with TTM2 (NEJM 2021), BOX, TAME, COACT and TOMAHAWK · 2025

   SupportsSection 7 of the resuscitation chapter: actively prevent fever at or below 37.5 °C for at least 72 hours, with routine induced hypothermia at 33 °C no longer preferred and the legacy 32–36 °C option removed; emergency coronary angiography for ST elevation with a selective strategy otherwise, following COACT and TOMAHAWK; oxygen saturation 94–98% and normocapnia; mean arterial pressure supported; and neuroprognostication deferred at least 72 hours after normalising temperature and sedation, using several independent findings rather than one.

   Read it asThis is a genuine reversal and it is recent. Deliberate cooling to 33 °C was standard for two decades on the strength of two small 2002 trials; TTM2 found it no better than strict normothermia, and the 2025 guidelines removed the older target entirely. Fever prevention is the part that survived. Anyone taught the 33 °C protocol learned current practice at the time and is now out of date, which is why the chapter flags the change explicitly rather than simply stating the new target.

   Strong

2. Resuscitation Council UK Guidelines 2025

   Resuscitation Council UK · Published late 2025, current

   SupportsAdult and paediatric basic life support throughout the resuscitation chapter: 30:2 for adults at 5–6 cm and 100–120/min; paediatric 5 rescue breaths then 15:2 at a third of chest depth; and the 2025 changes — calling 999 for an unresponsive person before assessing breathing, AEDs usable at any age including infants, thumb-encircling compressions for infants, and the revised child pad placement.

   Read it asCurrency matters unusually here. The 2021 guidelines are still widely quoted in training material and in charts written before the update, and several points differ. Anything on this site that conflicts with a 2021-era source is deliberate.

   Strong

3. Emergency treatment of anaphylaxis: guidelines for healthcare providers

   Resuscitation Council UK · May 2021, with the 2021 evidence review in Resuscitation

   SupportsThe IM adrenaline doses by age, repeating after 5 minutes, the definition of refractory anaphylaxis as no improvement after two appropriate doses, the positioning guidance, and the risk-stratified observation periods.

   Read it asTwo changes in the 2021 update are still not universally known: corticosteroids are no longer recommended for routine emergency treatment, and the repeat interval is 5 minutes rather than the 10–15 some older material gives. The doses are chosen to be safely and quickly drawn up rather than precisely weight-derived, which the guideline states explicitly.

   Strong

4. NICE NG143 — Fever in under 5s, and the traffic light system

   National Institute for Health and Care Excellence, NG143 · 2019, updated 2025

   SupportsThe three-band assessment and the paediatric thresholds on the vital signs page: that the highest single feature present sets the band; the red features including pale, mottled, ashen or blue skin, no response to social cues, not waking or not staying awake, a weak high-pitched or continuous cry, grunting, a respiratory rate above 60, moderate or severe chest recession, reduced skin turgor, a bulging fontanelle, neck stiffness, a non-blanching rash and focal or prolonged seizures; the amber features including impaired social cues, nasal flaring, oxygen saturation of 95% or less, dry mucous membranes, poor feeding, capillary refill of 3 seconds or more and reduced urine output; the age-specific respiratory thresholds of 60, 50 and 40 per minute for 0–5 months, 6–12 months and over 12 months; that a temperature of 38 °C or above under 3 months is a red feature and 39 °C or above at 3–6 months is amber; that fever of 5 days or more prompts assessment for Kawasaki disease; and that neither the height nor the duration of fever predicts serious illness.

   Read it asTwo things the guideline says that are worth quoting to anyone who suggests otherwise: a parent’s report of fever should be taken seriously without a thermometer reading, and the classic meningitis signs are often absent in infants with bacterial meningitis. A general practice cohort of 6,703 children — Kerr, Verbakel et al., Accuracy of the NICE traffic light system in children presenting to general practice, British Journal of General Practice 2022;72(719):e398 — found that impaired social cues alone triggered 97% of amber and 61% of red classifications, while abnormal vital signs contributed to only a small fraction — which is the evidence behind the page leading on behaviour rather than numbers. NG143 also carries its own warning that pulse oximeters can overestimate saturation in people with dark skin.

   Strong

5. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension

   European Society of Cardiology, 2024; with commentary in Circulation and Hypertension on the reclassification · 2024

   SupportsThe divergence noted in the blood pressure chapter: three categories replacing the previous scheme — non-elevated below 120/70, elevated at 120–139 or 70–89, and hypertension at 140/90 or above — with the stages abandoned, and a treatment target of systolic 120–129 where tolerated.

   Read it asThe definition of hypertension did not move; the labels below it did. Published commentary notes that someone with an office reading of 118/72 was “optimal” under the 2018 and 2023 European schemes and is “elevated” under this one purely on a diastolic value in the seventies, and that the diastolic evidence for “lower is better” is weaker than the systolic evidence. UK practice follows NICE NG136, which retains 140/90 and the staging. The chapter presents both rather than picking, because a reader may be shown either table.

   Strong

6. Anti-choking suction devices — regulatory position and evidence

   MHRA Device Safety Information alert on counterfeit and unbranded anti-choking devices; FDA De Novo classification of LifeVac under 21 CFR 874.5400; Resuscitation Council UK position; AHA, American Red Cross, AAP and ILCOR positions; Ramaswamy et al. cadaver study, Laryngoscope 2023; Haupt et al. pilot cadaveric study, Resuscitation Plus 2025; and the 2020 systematic review and 2023 manikin study · 2020–2026

   SupportsThe device section in choking and drowning: that the FDA De Novo classification creates the device type “suction anti-choking device as a second-line treatment”; that LifeVac and Dechoker are the only two brands with valid UKCA or CE marking and MHRA registration in the UK, both registered for use only after back blows and abdominal thrusts have failed; that the MHRA estimates over 10,000 counterfeit or unbranded devices were bought by the UK public in two years and warns they may fail or worsen the obstruction because they lack a functioning one-way valve; that RCUK neither encourages nor discourages while declining to endorse them on insufficient evidence; and that cadaveric testing found Dechoker failed in every trial while LifeVac cleared only moistened crackers, with both applying significant pressure to the tongue.

   Read it asThe commonly repeated claim that these devices are “not FDA approved” is out of date — the De Novo classification changed that, and it changed it specifically by creating a second-line device type. The accurate criticism is not that they are unapproved but that the favourable evidence is manufacturer-held self-report and manikin work whose own systematic review rated certainty as very low, while independent cadaveric testing was unfavourable. The counterfeit market is the part that is unambiguously dangerous. The behavioural risk — a device substituting for training in back blows and thrusts — is raised by several of the bodies above and is not a small consideration.

   Moderate

7. Heat stroke — recognition and cooling

   European Resuscitation Council First Aid Guidelines 2025 (based on the 2025 ILCOR consensus); Society of Critical Care Medicine, Guideline for the Treatment of Heat Stroke, Crit Care Med 2025;53(2):e490–e500; with a 2025 Annals of Emergency Medicine description of an in-department cold-water immersion protocol · 2025

   SupportsThe heat chapter: heat stroke defined as core temperature at or above 40 °C with central nervous system dysfunction; whole-body cold water immersion from 1 to 26 °C continued until core temperature falls below 39 °C, with ice water at 1–5 °C giving the fastest rate; active cooling preferred over passive; the alternatives where immersion is impossible, including tarp-assisted cooling, ice sheets, packs to neck, axillae and groin, and evaporative cooling with fanning; cool first and transport second, targeting below 39 °C within 30 minutes of onset; and that rectal temperature is the only reliable measurement, with tympanic, temporal, oral, axillary and infrared readings inaccurate at the extremes.

   Read it asThe 60% intensive-care mortality and the roughly one-third of survivors with lasting cognitive or motor impairment are what justify the urgency of the cooling instruction. The published case in which a tympanic thermometer read 36.7 °C against a rectal 41.1 °C is quoted on the page because it is the clearest possible demonstration that a normal-looking ear reading excludes nothing. Paediatric immersion is a genuine evidence gap — there is little data below about 12 years, children cool faster for their size, and the chapter therefore recommends evaporative cooling with frequent checks rather than immersion.

   Strong

8. Accidental hypothermia, and electrical and crush injury

   European Resuscitation Council Guidelines 2025 on special circumstances and first aid; UK Search and Rescue and wilderness medicine consensus on rewarming and frostbite; disaster medicine literature on crush syndrome · 2025

   SupportsThe cold chapter: hypothermia staging, gentle handling and horizontal positioning because of myocardial irritability, core rather than peripheral rewarming, afterdrop and rewarming collapse, prolonged resuscitation with rewarming, and frostbite rewarming at 37–39 °C with the instruction not to thaw where refreezing is possible. The electrical chapter: isolating the supply before contact, standoff from overhead lines, entry and exit wounds with deep tissue injury, and reverse triage in lightning strike. The crush chapter: crush syndrome from potassium and myoglobin release on reperfusion, fluid resuscitation before release, and that tourniquets are not recommended to prevent it.

   Read it asTwo points on the page go slightly beyond guideline text and are flagged as judgements. The fifteen-minute crush threshold is a widely used working figure rather than a validated cut-off, and the chapter says so and instructs that unknown timing be treated as prolonged. And the chapter deliberately declines to tell a lone bystander to leave someone trapped — it states the preference for release alongside fluids while making clear that a person who lifts the load has not acted recklessly, because the alternative framing produces paralysis at a scene.

   Strong

9. Resuscitation Council UK First Aid Guidelines 2025

   Resuscitation Council UK · 2025, current

   SupportsThe escalating approach in choking — cough, back blows, abdominal thrusts, with no blind finger sweeps and mandatory clinical assessment for anyone who has received thrusts; the escalation in life-threatening bleeding from manual direct pressure to haemostatic dressing and tourniquet; and the drowning sequence of flotation, removal from water and prevention of hypothermia.

   Read it asThe bleeding escalation is the notable one: tourniquets sit in the guidance as a step in a sequence rather than as a desperate last resort, which reverses what many older first aid courses taught.

   Strong

10. Supplying take-home naloxone without a prescription

    UK Government guidance, following The Human Medicines (Amendments Relating to Naloxone and Transfers of Functions) Regulations 2024 · Regulations December 2024; guidance updated 2025

    SupportsThat anyone may administer naloxone in an emergency; that it remains a prescription-only medicine so pharmacies cannot sell it over the counter; and that since December 2024 a much wider group may supply take-home and carry kits without a prescription — drug and alcohol services, pharmacy professionals, registered nurses and midwives, paramedics, police forces, prison and probation staff, and armed forces medical services.

    Read it asThe clinically important point is not legal but pharmacological: naloxone has a shorter duration of action than most opioids, so a person can stop breathing again after apparently full reversal. Synthetic opioids in the current UK supply, including nitazenes and fentanyl, frequently need repeated doses.

    Strong

11. Normal ranges of heart rate and respiratory rate in children from birth to 18 years

    Fleming S, Thompson M, Stevens R, et al., Lancet 2011;377(9770):1011–1018 · 2011

    SupportsThe heart rate and respiratory rate bands in the school charts, alongside APLS reference ranges and the 2017 AAP paediatric blood pressure guideline.

    Read it asReference ranges genuinely disagree between sources. Comparisons of APLS, PALS and the Fleming and O’Leary centiles show the published limits sitting in different places, with PALS upper limits falling outside the 99th centile in some age bands. The chart on this site had to choose, and the alert bands are a judgement about when to escalate rather than a published boundary. That is stated on the page.

    Strong

12. Button battery ingestion — time-critical management and the honey protocol

    UK paediatric transport and regional network guidelines (KIDS, NWTS, East of England ODN) and NHS trust patient information · 2017–2025

    SupportsThat a battery lodged in the oesophagus is an emergency even in an asymptomatic child, that damage can begin within two hours and removal is targeted inside that window, that over half of fatalities involve delayed or missed diagnosis, and that life-threatening bleeding can occur up to 28 days after removal or passage. And the honey protocol: children over 12 months, 10 ml every 10 minutes, where ingestion is known or suspected within 12 hours, otherwise nil by mouth.

    Read it asHoney is excluded under 12 months because of infant botulism risk, and where perforation is suspected. Ordinary commercial honey rather than artisanal. Risk falls sharply once the battery is past the stomach, but that determination needs an x-ray and is not a decision to make at home.

    Strong

13. NICE NG95 Lyme disease, and NG184 on antimicrobial prescribing for bites and stings

    National Institute for Health and Care Excellence · NG95 2018 with updates; NG184 2020

    SupportsThe bites and stings chapter: that erythema migrans appears 3–30 days after a bite, expands, is often not a bullseye and is not usually itchy or painful; that it should be diagnosed clinically and treated without waiting for serology; that antibiotic prophylaxis after a tick bite is not routinely recommended in the UK; and that antibiotics are not indicated for a bite where the skin is unbroken.

    Read it asThe no-prophylaxis position differs from practice in some other countries, so patients ask for it. It rests on a benefit-against-harm judgement rather than on evidence that transmission does not occur, and the safety net is surveillance for the rash. Around 60–80% of UK Lyme cases develop erythema migrans, so its absence does not exclude the diagnosis.

    Strong

14. Button battery ingestion triage — National Capital Poison Center guideline and ESPGHAN position

    National Capital Poison Center Button Battery Ingestion Triage and Treatment Guideline; and the ESPGHAN position paper on foreign body ingestion in children · current

    SupportsThe honey protocol in poisoning: honey for children over 12 months where ingestion is known or suspected within the preceding 12 hours, at intervals while in transit, to coat the battery and slow alkaline injury; with exclusions under 12 months for infant botulism risk and where perforation is suspected. Both bodies also underpin the two-hour removal target for an oesophageal battery and the point that a battery past the stomach carries much lower risk.

    Read it asThe honey recommendation is derived from animal and ex-vivo work on pH neutralisation rather than from randomised human trials, and is a mitigation while in transit rather than a treatment. It never substitutes for going, which is what the page says.

    Strong

15. Rabies risk assessment, including bats in the UK

    UK Health Security Agency rabies risk assessment guidance · current

    SupportsThat there is no indigenous rabies in UK animals other than bats, and that bat contact anywhere — including in the UK — warrants urgent assessment for post-exposure treatment, as does any mammal bite or scratch abroad.

    Read it asThe bat exception is the part most often missed, because the general message that Britain is rabies-free is otherwise correct.

    Strong

16. Inter-arm blood pressure difference, and cuff sizing

    NICE NG136 on measuring both arms; AHA cuff-sizing standards; and cohort evidence including the Fasa Adults Cohort Study and pooled inter-arm analyses · 2019–2025

    SupportsThat blood pressure should be measured in both arms at diagnosis, that a difference above 15 mmHg should be repeated and, if it persists, the higher arm used thereafter; that bladder width should be about 40% and length at least 80% of arm circumference; and that an undersized cuff overestimates systolic pressure by roughly 10–15 mmHg and sometimes 20.

    Read it asThe association between a persistent inter-arm difference and cardiovascular risk is observational and the thresholds proposed in the literature vary from 5 to 15 mmHg. The action the difference triggers — use the higher arm, and think about dissection in the right clinical context — is what the page rests on rather than a precise risk estimate.

    Moderate

17. Water compared with other solutions for wound cleansing

    Fernandez R, Green HL, Griffiths R, Atkinson RA, Ellwood LJ. Water for wound cleansing. Cochrane Database of Systematic Reviews 2022, Issue 9, CD003861 · Fifth update, 14 September 2022

    SupportsThat potable tap water is a reasonable irrigant for uncomplicated acute wounds, with no demonstrated increase in infection against sterile saline.

    Read it asThe certainty fell when the review was updated. Earlier versions concluded tap water should be preferred on cost and availability; the 2022 fifth update, covering 13 trials, rates the evidence low to very low certainty, the trials being small and inconsistent in how infection was defined. The practical recommendation stands — there is no case for delaying irrigation to find saline — but as reasonable practice rather than proven superiority. The trials also excluded bites, punctures, heavily contaminated wounds, foreign bodies and immunocompromised patients, which are precisely the wounds that need a clinician.

    Moderate

18. Pulse oximetry limitations, including skin pigmentation

    Regulatory safety communications from the MHRA and FDA, and the paediatric pulse oximetry literature · 2021–2025

    SupportsThat pulse oximeters can overestimate true oxygen saturation in people with darker skin, that carboxyhaemoglobin is read as oxyhaemoglobin so readings are falsely high in carbon monoxide poisoning, that poor perfusion and movement make readings unreliable, and that cyanosis is not clinically evident until saturation falls below about 85%.

    Read it asThe pigmentation bias is the newest of these and the least widely known. None of it makes the device useless; all of it means the reading is evidence rather than an answer.

    Strong

Consumer ECG devices

1. Clinical Validation of 5 Direct-to-Consumer Wearable Smart Devices to Detect Atrial Fibrillation — the BASEL Wearable Study

   JACC: Clinical Electrophysiology 2022 · 2022

   SupportsThe figures in the ECG chapter: against a simultaneous physician-read 12-lead ECG in 163 patients, sensitivity for atrial fibrillation of 84–96% and specificity of 91–98% across five devices once inconclusive tracings are excluded; inconclusive rates of 17–26%, with only 79% of recordings returning an automated diagnosis; and 8% of patients in sinus rhythm labelled as AF by at least one device.

   Read it asThe inconclusive rate is the part usually omitted when these sensitivities are quoted, and the chapter leads with it. Manual review resolved the rhythm in about 99% of tracings, so an inconclusive result is generally an algorithm limitation rather than a bad recording — which is why the advice is to keep the trace. Validation populations are adult and older, mean ages in the mid-sixties.

   Strong

2. Accuracy and clinical relevance of the single-lead Apple Watch electrocardiogram to identify atrial fibrillation

   Cardioversion cohort study, 74 patients · 2022

   SupportsThe repeat-once rule: repeating an unclassified recording once reduced the unclassified rate substantially, while a third attempt lowered accuracy and produced false positives.

   Moderate

Vaping

1. Carbonyl and metal emissions in e-cigarette aerosol

   Pooled analyses of aerosol chemistry, including a 2023 health risk assessment in Scientific Reports and the Farsalinos carbonyl systematic review in Frontiers in Physiology · 2017–2023

   SupportsThe per-puff yields behind the exposure estimator: mean formaldehyde around 0.86 µg/puff with a reported maximum near 28 µg/puff, acetaldehyde around 0.67 and acrolein around 0.37, with metals from nichrome heating elements.

   Read it asThe single most important caveat in this literature. The highest published carbonyl figures come from machine protocols producing “dry puff” conditions — the coil hot with insufficient wicking — which a person finds acutely unpleasant and stops doing. Quoting those as ordinary use is the commonest error in the field. Yields span roughly three orders of magnitude with power and device, which is why the estimator separates device power from puff frequency and why its high-power figures sit well below the published maxima.

   Moderate

2. Cancer and non-cancer risk from metals in e-cigarette liquids and aerosols

   International Journal of Environmental Research and Public Health 2020;17(6):2146 · 2020

   SupportsThat chromium and nickel from nichrome coils appear to be the main contributors to calculated cancer and non-cancer risk from vaping, and that those calculated risks exceeded those from formaldehyde and acetaldehyde in the same devices.

   Read it asUnder-appreciated relative to the aldehydes, which get the coverage. This is a modelled risk assessment from measured concentrations, not an outcome study — there is no cohort showing cancers caused by coil metals.

   Moderate

3. Relative cancer potency of e-cigarette emissions against tobacco smoke

   Stephens WE, modelling analysis of emissions data; and the 2018 National Academies consensus report on the public health consequences of e-cigarettes · 2017–2018

   SupportsThe denominator the estimator keeps visible: most e-cigarette emissions were modelled at cancer potencies below 1% of tobacco smoke, with exceptions; and the National Academies conclusion that cancer risk from long-term e-cigarette use, if any, is likely very low compared with combustible cigarettes.

   Read it asMass is not potency, and the estimator says so. Vape aerosol can approach a cigarette on formaldehyde by weight while remaining far below on total carcinogenic potency, because the nitrosamines and polycyclic aromatic hydrocarbons that carry most of tobacco smoke’s potency are largely absent rather than merely reduced. Modelling, not outcomes — there are no thirty-year cohorts, which is also why the estimator refuses to output a risk percentage.

   Moderate

4. Use of e-cigarettes among young people in Great Britain

   Action on Smoking and Health (ASH) · 2026 survey

   SupportsYouth prevalence figures, the fall in disposable use from 69% to 13% among young vapers, and the finding that 62% of young people believe vaping is as harmful as smoking or worse.

   Read it asSelf-reported survey data. The disposables collapse is well evidenced; the claim that youth vaping itself has fallen proportionally is not, and this site says so.

   Moderate

5. Disposable vapes banned from 1 June 2025

   UK Government · In force 1 June 2025

   SupportsThe regulatory timeline on what changed in UK law.

   Read it asMade under environmental rather than tobacco legislation, which is why the ban covers single-use devices rather than nicotine content.

   Strong

Eyes and sight

Glaucoma detection and the UK treatment pathway, macular degeneration, and the two things currently promoted as neuroprotection.

1. Glaucoma: diagnosis and management (NG81)

   NICE · Published 2017, updated 26 January 2022

   SupportsThe UK treatment pathway: 360-degree selective laser trabeculoplasty as a first-line option for open-angle glaucoma and ocular hypertension, rather than lifelong drops.

   Read it asThe January 2022 update is the operative change and the reason this topic leads with it. It does NOT support any claim about lifestyle prevention of glaucoma, and no such claim is made anywhere in the topic.

   Moderate

2. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT)

   Gazzard et al., Lancet 2019; six-year results Ophthalmology 2023;130(2):139-151 · 2019, extended 2023

   SupportsSLT as a reasonable first-line treatment. Treatment-naive patients, six UK hospitals, observer-masked.

   Read it asThe primary outcome was health-related quality of life, NOT sight preserved. That is why this site grades SLT as a reasonable first-line option and explicitly not as superior to drops for preserving vision.

   Moderate

3. Latanoprost-netarsudil for previously treated open-angle glaucoma or ocular hypertension (TA1009)

   NICE; netarsudil (Rhokiinsa) has held a UK marketing authorisation since November 2019 · Checked August 2026

   SupportsThat Rho kinase inhibitors ARE available in the UK, and that the latanoprost-netarsudil combination is NICE-recommended for adults already treated for open-angle glaucoma or ocular hypertension.

   Read it asAdded round 115 to correct the glaucoma chapter, which had placed netarsudil in its US-only section. That was wrong and it is the kind of error that sends a reader to ask for something abroad that their own optometrist can already discuss. It does NOT support any claim about where in the sequence the combination sits relative to SLT or a prostaglandin alone.

   Moderate

4. Position Statement on Nicotinamide Use for Glaucoma Neuroprotection

   American Glaucoma Society and American Academy of Ophthalmology · 2025

   SupportsThe Emerging grade on nicotinamide, and the caution about gram doses.

   Read it asReviews the phase 2 work — 32 participants in the US on nicotinamide plus calcium pyruvate, 57 in Australia in crossover — and concludes the endpoints are functional findings detectable in a research setting that do not consistently translate into visual recovery meaningful to the patient. It does not support recommending nicotinamide, and this site does not.

   Moderate

5. Ocular Hypertension Treatment Study (OHTS)

   Kass et al. and the OHTS Group; 22 US clinical centres, 1,636 participants · Primary outcome 2002; corneal thickness analyses 2001 and 2020; 20-year follow-up

   SupportsThe five-year conversion figures (9.5% untreated against 4.4% treated), the risk stratification from about 1-2% to 25-35% over five years, and the five baseline predictors: age, IOP, central corneal thickness, cup-to-disc ratio and visual field pattern standard deviation. Also the corneal thickness figures: mean 573 micrometres, 24% above 600, and African American participants averaging about 23 micrometres thinner.

   Read it asThe trial predates OCT, so early structural damage may have been under-detected — which if anything makes the conversion figures conservative. It does NOT support any statement about how fast an individual will progress; this site gives ranges and says explicitly that rate cannot be known at diagnosis.

   Moderate

6. Glaucoma pipeline and sustained-release delivery: Durysta, iDose TR and what follows them

   FDA approvals (Durysta March 2020, iDose TR December 2023); Glaucoma Research Foundation; Review of Ophthalmology 2026 pipeline; Ophthalmology Times 2026 · Availability position checked August 2026

   SupportsThe US-only treatment section and the pipeline section: the iDose phase 3 pressure reductions of 6.6-8.4 mmHg across 1,150 patients, the Durysta single-administration limit and its roughly 3.5% corneal endothelial cell loss at 18 months, and the biodegradable latanoprost implant reporting 26-35% reduction over 48 weeks with 94% needing no drops.

   Read it asAVAILABILITY WILL AGE. These are stated as approved in the United States and not available in the UK at the time of writing, and the page is date-stamped and says so. Anything here should be re-checked rather than relied on. Trade names appear because a reader will meet them in American coverage and needs to recognise what they are reading; no product is recommended.

   Moderate

7. The Portfolio Diet: the JAMA 2011 trial, the metabolic-ward studies, and the pooled analysis

   Jenkins et al., JAMA 2011;306:831-9 (351 participants, four Canadian centres, six months); Jenkins et al. 2003, metabolically controlled, against 20mg lovastatin; Chiavaroli et al., Prog Cardiovasc Dis 2018, pooled analysis · Checked August 2026

   SupportsLDL reduction of 13.8% on intensive portfolio advice and 13.1% on routine advice against 3.0% on a low-saturated-fat control, in free-living people over six months, with NO significant difference between the two portfolio arms (P = 0.66); about 17% pooled across controlled trials; 28-35% under metabolically controlled conditions, and -28.6% against -30.9% for 20mg lovastatin in the head-to-head.

   Read it asSCOPE. The 28-35% figure comes from feeding studies where every meal was provided, and is a ceiling rather than an expectation; the chapter leads with 13-17% for that reason. There is NO trial of this dietary pattern with cardiovascular events as an endpoint, and the site grades it Strong for LDL and Moderate for events, the latter inferred from the LDL evidence rather than demonstrated. The absorber-versus-producer explanation for variable response is stated as plausible mechanism and has NOT been verified against a source.

   Moderate

8. Healthier You: the NHS Diabetes Prevention Programme

   NHS England; national service evaluation of the first 324,699 referrals; cohort analysis of the first 36,000 patients · Programme from 2016; universal English coverage by 2018; checked August 2026

   SupportsEligibility at HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L within 12 months, 18 or over, not pregnant, no diabetes diagnosis; a history of gestational diabetes qualifying regardless of HbA1c; nine months, at least 13 group sessions and a minimum 16 hours, with a digital alternative. Completer outcomes of about -3.6 kg and -2.1 mmol/mol. And the funnel: of 324,699 referred, 53% attended initial assessment, 36% attended at least one session, 19% completed.

   Read it asThe completion figure is the load-bearing one and the chapter uses it as an argument for choosing a format you will finish, not as an argument against the programme. It does NOT support any claim about how many people in the band progress to diabetes, which the chapter deliberately gives as varying rather than as a figure.

   Moderate

9. Menopause: identification and management (NG23), and the randomised evidence on hormone therapy and cognition

   NICE NG23 (2024 update); KEEPS-Cog and ELITE, with the KEEPS continuation (2024); Andy et al., Frontiers in Endocrinology 2024; systematic review in Lancet Healthy Longevity, December 2025 · Checked August 2026

   SupportsThat NICE says do not offer hormone therapy to prevent dementia and describes the evidence on cognitive symptoms as uncertain; and that for cognitive PERFORMANCE started near the transition the randomised answer is neutral - KEEPS-Cog and ELITE both null, the KEEPS continuation null about a decade on.

   Read it asThe distinction is the point. The randomised question has been answered for cognitive performance and remains open for dementia INCIDENCE, where the observational cohorts conflict. An earlier version of the chapter said the timing hypothesis had never been tested, which was right for incidence and wrong for performance. None of this supports any statement about hormone therapy for SYMPTOMS, which this site does not cover.

   Moderate

10. Dry Eye Assessment and Management (DREAM) study, and its extension

    National Eye Institute; 535 patients, 27 centres · Primary result 2018; withdrawal extension 2019

    SupportsThat omega-3 supplementation at 3,000mg/day is no better than a refined olive oil placebo for moderate-to-severe dry eye, on symptoms or on any objective sign. Also the teaching point that BOTH arms improved substantially, by about 14 and 12.5 points, which is why uncontrolled dry eye testimonials are worth little.

    Read it asA meta-analysis pooling seventeen trials does report benefit. The site weights the single large well-controlled trial over the pooled smaller ones and says so on the page. The olive-oil placebo is the main published objection and is not settled.

    Moderate

11. Perfluorohexyloctane for dry eye: FDA approval, and the same molecule as a European medical device

    FDA approval May 2023 (Miebo, Bausch + Lomb / Novaliq); GOBI and MOJAVE phase 3 trials, >1,200 patients; sold in Europe and the UK over the counter as EvoTears and Hycosan Shield · Availability checked August 2026

    SupportsThat the first FDA-approved prescription drug targeting tear evaporation is the same molecule available here without prescription, and that it met both primary endpoints in its pivotal trials.

    Read it asAVAILABILITY AND REGULATORY ROUTE WILL AGE. A device authorisation is a lower evidential bar than a drug approval; the page says so rather than presenting the UK route as simply better. Product names appear because a reader meets them in American coverage, not as recommendations.

    Moderate

12. Age-Related Eye Disease Study 2 (AREDS2)

    National Eye Institute · 2013 onwards

    SupportsThe AREDS2 formulation, and the removal of beta-carotene on lung cancer risk in smokers and former smokers.

    Read it asCRITICAL SCOPE. Tested in people with intermediate AMD, or advanced AMD in one eye, for progression to advanced disease. It does NOT support taking the formula for prevention in someone with healthy maculae — which is how it is most often sold, and the chapter says so explicitly.

    Moderate